WO2013088452A2 - Quinoline derivatives as renin inhibitors - Google Patents

Quinoline derivatives as renin inhibitors Download PDF

Info

Publication number
WO2013088452A2
WO2013088452A2 PCT/IN2012/000726 IN2012000726W WO2013088452A2 WO 2013088452 A2 WO2013088452 A2 WO 2013088452A2 IN 2012000726 W IN2012000726 W IN 2012000726W WO 2013088452 A2 WO2013088452 A2 WO 2013088452A2
Authority
WO
WIPO (PCT)
Prior art keywords
piperidin
quinoline
carboxylic acid
amide
cycloalkyl
Prior art date
Application number
PCT/IN2012/000726
Other languages
French (fr)
Other versions
WO2013088452A3 (en
Inventor
Rajamannar Thennati
Biswajit Samanta
Ranjan Kumar Pal
Anil Savajibhai Kumbhani
Jay Prakashchandra Adhyapak
Nakul P AKOLKAR
Pravin PARMAR
Megha DUBEY
Original Assignee
Sun Pharma Advanced Research Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd. filed Critical Sun Pharma Advanced Research Company Ltd.
Publication of WO2013088452A2 publication Critical patent/WO2013088452A2/en
Publication of WO2013088452A3 publication Critical patent/WO2013088452A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel quinoline derivatives as renin inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of cardiovascular disorders related to hypertension, in warm-blooded animals. Further the present invention also provides a method for treatment of disorders like congestive heart failure, cardiac hypertrophy, cardiac fibrosis, coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism etc. BACKGROUND OF THE INVENTION
  • Hypertension is one of the major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death worldwide.
  • Inhibitors of the renin-angiotensin systems (RAS) are known to be successful treatments for hypertension. As renin specifically catalyses the rate- limiting step of the RAS, it represents the optimal target for RAS inhibition.
  • the first non-peptide renin inhibitors with high in vitro activity have been reported in PCT application WO 1997/00931 1.
  • Amine based non-peptidic renin inhibitors have been disclosed in WO2007/099509.
  • the quinoline derivatives disclosed in JP2010- 163361 (WO2008/136457) and JP2010-208947 are not considered to be the part of the present invention.
  • the present invention relates novel quinoline derivatives as renin inhibitors.
  • the present invention relates to compounds of formula (I),
  • X is selected from O or S;
  • Y is bond or a group selected from O or NH, with the proviso that Y is NH when X is S;
  • R is selected from the group consisting of substituted or unsubstituted -Ci -5 -linear or branched alkyl, -C3_ 8 -cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with C 1.3 -linear or branched alkyl group; R is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-C 1-8 -alkyl, -(CH 2 ) q O-C 3- 12 -cycloalkyl, -(CH 2 ) q CO-C,.
  • R 2 is selected from the group consisting of substituted or unsubstituted -Ci-i 2 -linear or branched alkyl, -(CH 2 ) q -C 3- i 2 -cycloalkyl, -(CH 2 ) q O-Ci. 8 -alkyl, -(CH 2 ) q O-C 3- i 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C, -8 -alkyl, -(CH 2 ) q CO-C 3 .
  • R 3 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted -Ci -8 -alkyl, -C 3- i 2 -cycloalkyl; or OR 2 and R 3 together with the carbon atom to which they are attached form a 3 to 6-
  • R" is a substitutent selected from -Ci -8 -alkyl cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
  • 'n' is an integer selected from 0, 1 and 2;
  • 'mi ', 'm 2 ' and 'm 3 ' are integers independently selected from 0, 1, 2, 3 and 4;
  • ( * ) at the ring carbon, indicate (R) or (S configuration or a racemate (RS).
  • One aspect of the present invention relates to compounds of formula (la),
  • Y is bond or oxygen (O);
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C3.12-cycloa.kyl, cycloalkylalkyl, -(CH ⁇ q O-Q.s-alkyl, ⁇ (CH 2 ) q CO -C
  • cycloalkyl -CO-aryl, -COOCi -8 -alkyl, -COOC 3- i 2 -cycloalkyl, -S0 2 Ci -8 -alkyl, -S0 2 - aryl, aryl, aralkyl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
  • R 2 is selected from the group consisting of substituted or unsubstituted -C 7- i 2 -linear or branched alkyl, -(CH 2 ) q -C 3 .i 2 -cycloalkyl, -(CH 2 ) q O-C,. 8 -alkyl, -(CH 2 ) q O-C 3- i 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-Ci.
  • Y is bond or oxygen (O); ' ⁇
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alk l, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, - -(CH 2 ) q CO- Ci-8-alkyI, -(CH 2 ) q CO-C 3 .i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COCi.
  • R 2 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -(CH 2 ) q -C 3 ., 2 -cycloalkyl -, -(CH 2 ) q O-C 1-8 -alkyl, -(CH 2 ) q O-C 3-]2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-Ci -8 -alkyl, -(CH 2 ) q CO-C 3- , 2 -cycloalkyl, - (CH 2 ) q CO-aryl, -COCi -8 -alkyl, -COC 3- i 2 -cycloalkyl, -CO-aryl, -COOC 1-8 -alkyl, - COOC 3 .i 2 -cycloalkyl, aralkyl
  • 'n' is an integer selected from 0, 1 and 2;
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci. 8 -linear or branched alkyl, -C 3 .i 2 -cycloalky[, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q CO- C,. 8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COC,. 8 -alkyl, -COC 3 .
  • R 2 is selected from the group consisting of substituted or unsubstituted -C 1-8 -linear or branched alkyl, -(CH 2 ) q -C 3- i 2 -cycloalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3 ., 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-Ci -8 -alkyl, -(CH 2 ) q CO-C 3 ., 2 -cycloalkyl, - (CH 2 ) q CO-aryl, -COC 1-8 -alkyl, -COC 3- i 2 -cycloalkyl, -CO-aryl, -COOCi.
  • Y is bond or oxygen (O); 1
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-C, -8 -alkyl, ⁇ (CH 2 ) q CO- Ci_ 8 -alkyl, -(CH 2 ) q CO-C 3 .i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COCi -8 -alkyl, -COC 3-12 - cycloalkyl, -CO-aryl, -COOC,.
  • R" is a substituted selected from -Ci.g-alkyl or -C3.i 2 -cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
  • Y is bond or oxygen (O);
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci. 8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci.
  • R is selected from the group consisting of substituted or unsubstituted -C 7- i 2 -linear or branched alkyl, - -(CH 2 ) q -C 3 -i 2 -cycloalkyl ⁇ (CH 2 ) q O-C 1-8 -alkyl, -(CH 2 ) q O-C 3-12 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C 1-8 -alkyl, -(CH 2 ) q CO-C 3-12 -cycloalkyl, - (CH 2 ) q CO-aryl, -COd.g-alkyl, -COC 3- i 2 -cycloalkyl, -CO-aryl, -COOC,.
  • 'n' is an integer selected from 0, 1 and 2;
  • 'mi ', 'm 2 ' and 'm 3 ' are integers independently selected from 0, 1, 2, 3 and 4;
  • ( * ) at the ring carbon indicate (R) or (S) configuration or racemate (RS).
  • Another aspect of the present invention relates to compounds of formula (If),
  • Y is bond or oxygen (O);
  • R is selected from the group consisting of substituted or unsubstituted -Ci -5 -linear or branched alkyl, -C 3 . 8 -cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci -3 -linear or branched alkyl group; R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-C 1-8 -alkyl, ⁇ (CH 2 ) q CO- C 1-8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COC 1-g -alkyl, -COC 3 .
  • R 2 is selected from the group consisting of substituted or unsubstituted -C 7 .i 2 -linear or branched alkyl, -(CH 2 ) q -C 3- i 2 -cycloalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3- i 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C 3 .
  • the invention also provides the use of compound of formula (la-If) or salt or N- oxides thereof for the preparation of pharmaceutical composition
  • pharmaceutical composition comprising compound of formula (la-If) or N-oxide thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof.
  • the present invention also provides a method for treatment of disorders like hypertension as well as congestive heart failure, cardiac hypertrophy, cardiac fibrosis coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism comprising administering to a mammal in need of such treatment an effective amount of compound of formula (Ia-If) or salt or N-oxides thereof.
  • disorders like hypertension as well as congestive heart failure, cardiac hypertrophy, cardiac fibrosis coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism
  • the present invention relates to compounds of formula (I),
  • Y is bond or a group selected from O or NH, with the proviso that Y is NH when X is S;
  • R is selected from the group consisting of substituted or unsubstituted -Ci.s-linear or branched alkyl, -C3 -8 -cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci -3 -linear or branched alkyl group;
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3- 12 -cycloalkyl, -(CH 2 ) q CO-C 1-8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, - COQ.g-alkyl, -COC 3- i 2 -cycloalkyl, -CO-aryl, -COOC 1-8 -alkyl, -COOC 3 - )2 -cycloalkyl, -S0 2 Ci_8-alkyl, -S0 2 -aryl, aryl,
  • R is selected from the group consisting of substituted or unsubstituted -Ci-i 2 -linear or branched alkyl, -(CH 2 ) q -C 3- i 2 -cycloalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3 . 12 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C 1-8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -.
  • R 3 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted -Ci -8 -alkyl, -C 3- i 2 -cycloalkyl; or OR 2 and R 3 together with the carbon atom to which they are attached form a 3 to 6-
  • R 'c' of the formula ( R ') p with optional one or more double bond
  • R" is a substitutent selected from -Ci -8 -alkyl or -C 3 _i 2 - cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
  • 'n' is an integer selected from 0, 1 and 2;
  • 'mi ', 'm 2 ' and 'm ' are integers independently selected from 0, 1, 2, 3 and 4;
  • ( * ) at the ring carbon, indicate (R) or (5) configuration or a racemate (RS).
  • Y is bond or oxygen (O);
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q CO- C 1-8 -alkyl, -(CH 2 ) q CO-C 3- , 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COC 1-8 -alkyl, -COC 3 .
  • R 2 is selected from the group consisting of substituted or unsubstituted -C 7 . ]2 -linear or branched alkyl, -(CH 2 ) q -C 3 .i 2 -cycloalkyl, -(CH 2 ) q O-Ci. 8 -alkyl, -(CH 2 ) q O-C 3- i 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C,.
  • 'n' is an integer selected from 0, 1 and 2;
  • R l is -Ci -8 -linear or branched alkyl group selected from methyl, ethyl, rc-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
  • R 1 is -COOCi -8 -alkyl, wherein -Ci -8 -alkyl group selected from methyl, ethyl, ⁇ -propyl, isopropyl, -butyl, isobutyl, and 1 , 1 -dimethylethyl (t-butyl).
  • R 1 is cycloalkylalkyl, selected from cyclopropylmethyl, cyclobutylethyl and cyclopentylethyl.
  • R 1 is -CH 2 0-Ci -8 -alkyl, wherein -Ci -8 -alkyl selected from methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, and 1 ,1-dimethylethyl (t-butyl).
  • R 2 is substituted or unsubstituted -C 7- i 2 -linear or branched alkyl group selected from heptyl, octyl, nonyl, decyl etc.
  • R 2 is -(CH 2 ) q -C 3- i 2 -cycloalkyl ring selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 2 is -(CH 2 ) q -C 4- i 2 -heterocyclic ring containing heteroatom oxygen or nitrogen, selected from tetrahydrofuran-2-ylmethyl, tetrahydropyran-4- ylmethyl, tetrahydrofuran-3-yl, oxetan, piperidine, pyrrolidine etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci-s-alkyl, halogen, trifluormethyl and -C3.i 2 -cycloalkyl etc.
  • R 2 is aryl or heteroaryl group selected from pyridine-2- ylmethyl, pyridine-3-ylmethyl and indan-2-yl.
  • R 2 is -CH 2 0-Ci. 8 -alkyl, wherein -Ci -8 -alkyl selected from methyl, ethyl, n-propyl, isopropyl, «-butyl, isobutyl, and 1,1-dimethylethyl (t-butyl).
  • R 2 is -CH 2 CO-Ci.8-alkyl, wherein -Ci.g-alkyl selected from methyl, ethyl, «-propyl, isopropyl, «-butyl, isobutyl, and 1,1-dimethylethyl (t-butyl).
  • R 2 is -CH 2 CO-C3_i 2 -cycloalkyl
  • the -C3_i 2 -cycloalkyl group is selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantan-l-yl.
  • R 2 is -CH 2 CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -Ci -8 -alkyl, halogen, trifluormethyl and -C3.i 2 -cycloalkyl.
  • R 2 is - (CH 2 ) q COheteroaryl trap wherein the heteroaryl group oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, qui
  • R 2 is -COCi -8 -alkyl, wherein -Ci -8 -alkyl selected from methyl, ethyl, ⁇ -propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
  • R 2 is -COC3.i 2 -cycloalkyl
  • the -C3.i 2 -cycloalkyl group is selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantan-l-yl.
  • R 2 is -CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -Ci -8 -alkyl, halogen, trifluormethyl and -C 3- i 2 -cycloalkyl.
  • R is -COOCj.g-alkyl, wherein -Ci.g-alkyl selected from methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
  • Y is bond or oxygen (O);
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3 .i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, - -(CH 2 ) q CO- C 1-8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COQ.g-alkyl, -COC M2 - cycloalkyl, -CO-aryl, -COOCi -8 -alkyl, -COOC 3- i 2 -cycloalkyl, -S0 2 C !-8 -alkyl, -S0 2 - aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and
  • R is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -(CH 2 ) q -C 3 -i 2 -cycloalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3 .
  • 'n' is an integer selected from 0, 1 and 2;
  • R 1 is -Ci -8 -linear or branched alkyl group selected from methyl, ethyl, «-propyl, isopropyl, rc-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
  • R 2 is -(CH 2 ) q -C 3 . ]2 -cycloalkyl ring which may contain one or more heteroatom selected from oxygen, nitrogen and sulphur and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3-12 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q CO- Ci. 8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COC,. 8 -alkyl, -COC 3-12 - cycloalkyl, -CO-aryl, -COOCi.
  • R 2 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -(CH 2 ) q -C 3 ., 2 -cycloalkyl, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3 .
  • 'n' is an integer selected from 0, 1 and 2;
  • R 1 is -COC 1-8 -alkyl, wherein -Ci -8 -alkyl selected from methyl, ethyl, tt-propyl, isopropyl, w-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
  • R 1 is -S0 2 Ci -8 -alkyl, wherein -C i -8 -alkyl selected from methyl, ethyl, «-propyl, isopropyl, rc-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
  • R 1 is -CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -C 1-8 -alkyl, halogen, trifluormethyl and -C3.i 2 -cycloalkyl.
  • R 2 is substituted or unsubstituted -C).
  • 8 -alkyl selected from methyl, ethyl, n-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
  • R 2 is -(CH 2 ) q -C3.i2-cycloalkyl ring which may contain one or more heteroatom selected from oxygen, nitrogen and sulphur and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6.
  • R 2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci -8 -alkyl, halogen, trifluormethyl and -C 3 .i 2 -cycloalkyl etc.
  • R 2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci -8 -alkyl, halogen, trifluormethyl and -C 3 .i 2 -cycloalkyl etc.
  • R 2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci -8 -alkyl, halogen, trifluormethyl and -C 3 .i 2 -cycloalkyl etc.
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C 3 .i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -g -alkyl, --(CH 2 ) q CO- Ci-s-alkyl, -(CH 2 ) q CO-C 3-12 -cycloalkyl, -(CH 2 ) q CO-aryl, -COCi -8 -alkyl, -COC 3- i 2 - cycloalkyl, -CO-aryl, -COOCi.
  • ring 'c' of the formula contains optionally one or more double bond
  • R" is a substitutent selected from -Ci -8 -alkyl or -C 3- i 2 -cycloalkyI and 'p' is an integer selected from 0, 1 or 2; ' ⁇ ' is an integer selected from 0, 1 and 2;
  • R 1 is -Ci-s-linear or branched alkyl group selected from methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
  • ring 'c' is 5-membered furan ring is substituted with one or more methyl group i.e. R" is a methyl group and 'p' is 1 or 2.
  • Y is bond or oxygen (O);
  • R 1 is selected from the group consisting of substituted or unsubstituted -Ci -8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, --(CH 2 ) q CO- Ci -8 -alkyl, -(CH 2 ) q CO-C 3- i 2 -cycloalkyl, -(CH 2 ) q CO-aryl, -COCi.
  • 'n' is an integer selected from 0, 1 and 2; 'mi ', 'm 2 ' and 'm 3 ' are integers independently selected from 0, 1, 2, 3 and 4;
  • R 1 is -Ci.g-linear or branched alkyl group, selected from methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (/-butyl).
  • R 2 is -(CH 2 ) q -C 3- i 2 -cycloalkyl ring selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6.
  • R 2 is -(CH 2 ) q -C4_i 2 -heterocyclic ring containing heteroatom oxygen or nitrogen, selected from tetrahydrofuran-2-ylmethyl, tetrahydropyran-4- ylmethyl, tetrahydrofuran-3-yl, oxetan, piperidine, pyrrolidine etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 2 is -CH 2 CO-Ci -8 -alkyl, wherein -C] -8 -alkyl selected from methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, and 1 ,1-dimethylethyl (t-butyl).
  • Y is bond or oxygen (O);
  • R is selected from the group consisting of substituted or unsubstituted -Ci.s-linear or branched alkyl, -C 3 . 8 -cycloalkyl and cycloalkylalkyl; wherein cyeloalkyl group may be optionally substituted with Ci -3 -linear or branched alkyl group; R 1 is selected from the group consisting of substituted or unsubstituted -Ci. 8 -linear or branched alkyl, -C 3- i 2 -cycloalkyl, cycloalkylalkyl, -(CH 2 ) q O-Ci -8 -alkyl, ⁇ (CH 2 ) q CO- C.
  • R 2 is selected from the group consisting of substituted or unsubstituted -C 7- i 2 -linear or branched alkyl, -(CH 2 ) q -C 3 .] 2 -cycloalkyl -, -(CH 2 ) q O-Ci -8 -alkyl, -(CH 2 ) q O-C 3- i 2 - cycloalkyl, -(CH 2 ) q O-aralkyl, -(CH 2 ) q CO-C 1-8 -alkyl, -(CH 2 ) q CO-C 3-12 -cycloalkyl, - (CH 2 ) q CO-aryl, -COCi -8 -alkyl, -COC 3-12 -cycloalkyl, -CO-aryl, -COOCi -8 -alkyl, - COOC 3- i 2 -cycloalkyl, aralkyl ary
  • 'n' is an integer selected from 0, 1 and 2;
  • R is -C[. 8 -linear or branched alkyl group, selected from methyl, ethyl, rt-propyl, isopropyl, M-butyl, isobutyl, and 1 , 1-dimethylethyl (i-butyl).
  • R is -C 3 -g-cycloalkyl, selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • R 1 is -Ci -8 -alkyl group selected from methyl, ethyl, w-propyl, isopropyl, w-butyl, isobutyl, and 1, 1-dimethylethyl (/-butyl).
  • R 2 is -(CH 2 ) q -C3.i 2 -cycloalkyl ring with the total number of carbon atom is more than six, selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
  • R 2 is -CH 2 CO-Ci -8 -alkyl, wherein -Ci -8 -alkyl selected from methyl, ethyl, rc-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
  • alkyl refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, either linear or branched, having from one to eight carbon atoms, both inclusive, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, «-propyl, 1-methylethyl (isopropyl), w-butyl, «-pentyl, and 1,1-dimethylethyl (t-butyl).
  • Ci -8 alkyl refers to an alkyl chain, linear or branched having 1 to 8 carbon atoms, both inclusive.
  • cycloalkyl denotes a non-aromatic mono-, or multicyclic ring system of 3 to about 12 carbon atoms.
  • Monocyclic rings include include, but are not limited to cylcopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Examples of simple multicyclic cycloalkyl groups include perhydronapththyl, perhydroindenyl etc; bridged multicyclic groups include adamantyl and norbornyl etc, and spriromulticyclic groups for e.g., spiro(4,4)non-2-yl.
  • all cycloalkyl groups described or claimed herein may be substituted or unsubstituted and may optionally contain one or more heteroatom selected from O, S and N.
  • cycloalkylalkyl refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group.
  • the cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
  • Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl and cyclopentylethyl.
  • all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted and may optionally contain one or more heteroatom selected from O, S and N.
  • alkoxy denotes an alkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are -OCH 3 and -OC 2 H 5 . Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • halogen or halo means fluorine, chlorine, bromine or iodine.
  • haloalkyl or haloalkoxy refers to an alkyl or alkoxy group substituted with one or more halogen atoms.
  • aryl refers to an aromatic radical having 6 to 14 carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems such as phenyl, naphthyl, tetrahydronapthyl, indanyl and biphenyl. Unless set forth or recited to the contrary, all aryl groups described or claimed herein may be substituted or unsubstituted.
  • arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH 2 C 6 H 5 and -C 2 H 4 C 6 H 5 . Unless set forth or recited to the contrary, all arylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • heteroaryl refers to substituted or unsubstituted 5 to 14 membered aromatic heterocyclic ring radicals with one or more heteroatom(s) independently selected from N, O or S.
  • the heteroaryl may be a mono-, bi- or tricyclic ring system.
  • the heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
  • heteroaryl ring radicals include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolinyl, isoquinolinyl, thiadiazolyl,
  • heteroaryl groups described or claimed herein may be substituted or unsubstituted.
  • heterocyclic ring or “heterocyclic radical” unless otherwise specified refers to substituted or unsubstituted non-aromatic 3 to 15 membered ring radical which consists of carbon atoms and from one to five hejeroatoms selected from nitrogen, phosphorus, oxygen and sulfur.
  • the heterocyclic ring radical may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
  • heterocyclic ring or heterocyclyl may optionally contain one or more olefinic bond(s).
  • heterocyclic ring radicals include, but are not limited to azepinyl, azetidinyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholanyl, decahydroisoquinolyl, indanyl, indolinyl, isoindolinyl, isochromanyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, oxadiazolyl, 2-oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl,
  • heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted.
  • heterocyclylalkyl refers to a heterocyclic ring radical directly bonded to an alkyl group.
  • the heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • Any asymmetric carbon atom may be present in the (R)-, (S)- or (Z?, ⁇ -configuration.
  • the compounds may thus be present as mixtures of stereoisomers or as pure stereoisomers.
  • the invention relates also to possible tautomers of the compounds of formula (la), (lb), (Ic), (Id), (Ie) and (If).
  • Salts of compounds of formula (la), (lb), (Ic), (Id), (Ie) and (If) are the physiologically acceptable salts.
  • Physiologically acceptable salts are particularly suitable for medical applications, due to their greater solubility in water compared with the starting or base compounds.
  • Suitable physiologically acceptable acid addition salts of the compounds of the invention may be salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, and the like or of organic acids such as, for example, acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, citric acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartartic acid, amino acids, such as glutamic acid or aspartic acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, and the like
  • organic acids such as, for example, acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, citric acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic
  • physiologically acceptable basic salts are ammonium salts, or suitable organic amines, such as tertiary monoamines, e.g. triethylamine or tris(2-hydroxyethyl)amine etc., alkali metal salts such as sodium salts and potassium salts and alkaline earth metal salts such as magnesium salts and calcium salts.
  • suitable organic amines such as tertiary monoamines, e.g. triethylamine or tris(2-hydroxyethyl)amine etc.
  • alkali metal salts such as sodium salts and potassium salts
  • alkaline earth metal salts such as magnesium salts and calcium salts.
  • 8-Cycloheptyloxy-4-(2-propoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide
  • 8-Cycloheptyloxy-4-(2-cyclopropylmethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide
  • 6-(2-Methoxyethoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)-piperidin-3-yl amide
  • 6-(3-Methoxypropoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)-piperidin-3-yl amide
  • the compounds of the formula (la) are obtained by converting compound of formula (1) to compound of formula (2) by alkylation at 8-hydroxy group of quinoline ring. Oxidation of methyl group at 2- position followed by further oxidation of carboxaldehyde derivative gives carboxylic acid derivative of formula (4).
  • the compound of formula (4) is coupled with 3- isopropylamino piperidine-1 -carboxylic acid fert-butyl ester to get compound of formula (5).
  • Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (6), which on removal of N-protecting group gives compound of formula (la).
  • compound of the formula (la) can be prepared by following the procedure as depicted in scheme 2. Displacement of halogen at 4-position of compound of formula (2) by corresponding alkoxyalcohol derivative gives compound of formula (7). Oxidation of methyl group at 2-position followed by further oxidation of carboxaldehyde derivative gives carboxylic acid derivative of formula (9). Compound of formula (9) is coupled with 3-isopropylamino piperidine-1 -carboxylic acid tert-butyl ester to give compound of formula (6), which on removal of N- protecting group gives compound of formula (la).
  • compound of the formula (lb) can be prepared by following the procedure as depicted in scheme 3. Reductive amination between compound of formula (8) and 3-amino piperidine-l-carboxylic acid te -butyl ester gives compound of the formula (10), which upon further reductive amination with acetone gives compound of formula (1 1). Removal of N-protecting group of compound of formula (1 1) gives compound of formula (lb).
  • compound of the formula (Ic) can be prepared by following the procedure as depicted in scheme 4. Displacement of halogen of compound of formula (5) by corresponding mercaptoalkyl amide derivative leads to the compound of formula (12). Removal of N-protecting group of compound of formula (12) gives compound of formula (Ic).
  • compound of the formula (Id) can be prepared by following the procedure as depicted in scheme 5. Alkylation of o-nitrophenol followed by cyclization at high temperature gives compound of formula (16). Alternatively, Claisen rearrangement of alkylated o-nitrophenol of formula (14) followed by its cyclization gives same cyclized derivative of formula (16). Reduction of nitro group followed by reaction with dimethyl acetylene dicarboxylate leads to the formation of corresponding quinoline derivative of formula (18). Conversion of hydroxyl group to halogen derivative followed by hydrolysis of ester gives compound of formula (20).
  • compound of the formula (Ie) can be prepared by following the procedure as depicted in scheme 6.
  • the compound of formula (4) is coupled with N-isopropylamino derivative in which the amino group is either directly attached to N-boc protected azetidine and pyrrolidine derivatives or via a methylene group to N-boc protected azetidine, pyrrolidine and piperidine derivatives to get compound of formula (23).
  • Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (24), which on removal of N-protecting group gives compound of formula (Ie).
  • compound of the formula (If) can be prepared by following the procedure as depicted in scheme 7.
  • the compound of formula (4) is coupled with 3-alkylamino piperidine-l-carboxylic acid tert-butyl ester to get compound of formula (25).
  • Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (26), which on removal of N-protecting group gives compound of formula (If).
  • the compounds described herein including compounds of general formula (la), formula (lb), formula (Ic), formula (Id), formula (Ie), and formula (If) can be prepared by techniques known to in the art, for example, through the reaction scheme depicted in Schemes 1-7. Furthermore, in the following examples, where specific acids, bases, reagents, coupling agents, solvents, etc. are mentioned, it is understood that other suitable acids, bases, reagents, coupling agents etc. may be used and are included within the scope of the present invention. Modifications to reaction conditions, for example, temperature, duration of the reaction or combinations thereof are envisioned as part of the present invention. The compounds obtained by using the general reaction scheme may be of insufficient purity. These compounds can be purified by any of the methods for purification of organic compounds known in the art, for example, crystallization or silica gel or alumina column chromatography using different solvents in suitable ratios.
  • Step I Preparation of 4-chIoro-8-cycloheptyloxy-2-methyl quinoline
  • Method-A N,N-Di-isopropylethylamine (9.5 mL, 0.055 mol) is added to a stirred solution of cycloheptanol (4.2 g, 0.036mol) in dichloromethane (42 mL) at room temperature and stirred for 5 minutes. Reaction mixture is cooled to 0-5°C, methanesulphonylchloride (3.4 mL, 0.044 mol) is added dropwise manner to the reaction mixture and stirred for 30 minutes. D. M.
  • Step II Preparation of 4-chloro-8-cyc.ohepty.oxy quinoline-2-carbaldehyde.
  • Selenium dioxide (1.35 g, 0.012 mol) is added to a stirred solution of 4-chloro-8- cycloheptyloxy-2 -methyl quirioline (2.8 g, 0.009 mol) in 1,4-dioxane (28 mL) at room temperature and then heated at 75°C for 40 minutes. Reaction mixture is cooled to room temperature, filtered through celite bed and washed with 1,4-dioxane (3x20 mL).
  • Step III Preparation of 4-chloro-8-cycloheptyIoxy quinoline-2-carboxylic acid.
  • An aqueous solution (50 mL) containing sodium chlorite (2.93 g, 0.026 mol, 80%) and sodium dihydrogen orthophosphate dihydrate (8.1 g, 0.052 mol) is added to a heterogeneous solution of 4-chloro-8-cycloheptyloxy quinoline-2-carbaldehyde (2.6 g, 0.009 mol) in te -butanol (50 mL) at room temperature and stirred for 1 hr.
  • Step IV Preparation of (R)-3-[(4-chloro-8-cycloheptyloxy quinoline-2-carbonyl)- isopropyIamino]-piperidine-l-carboxylic acid ter/-butyl ester.
  • Step V Preparation of (R)-3- ⁇ [8-cycloheptyloxy-4-(2-methoxy ethoxy)quinoline- 2-carbonyl]-isopropylamino ⁇ piperidine-l-carboxyIic acid tert-butyl ester.
  • Potassium tert-butoxide (0.07 g, 0.0006 mol) is added to a stirred solution of 2- methoxy ethanol (0.04 mL, 0.0006 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 10 minutes.
  • a solution of (R)-3-[(4-chloro-8- cycloheptyloxy quinoline-2-carbonyl)isopropylamino]piperidine- 1 -carboxylic acid tert-butyl ester (0.23 g, 0.0004 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr.
  • Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate.
  • Step VI Preparation of 8-cycloheptyloxy-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide dihydrochloride.
  • Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8- cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide dihydrochloride.
  • Examples 2-121 are prepared according to the similar procedure as described in Example 1 , using appropriate starting material and reagents. Table 1:
  • Step I Preparation of 4-chloro-8-cyclohexylmethoxy-2-methy! quinoline.
  • Potassium carbonate (5.84 g, 0.042 mol) is added to a stirred solution of 4-chloro-2- methyl quinolin-8-ol (2.0 g, 0.01 mol) in N,N-dimethylformamide (30 mL) at room temperature and stirred for 15 minutes.
  • Cyclohexyl methyl bromide (3.56 mL, 0.026 mol) is added to the reaction mixture and then heated at 90°C for 3 hrs and 30 minutes. Reaction mixture is cooled to 10-15°C, D. M.
  • Step II Preparation of 8-cyclohexylmethoxy-4-(2-methoxyethoxy)-2-methyl quinoline.
  • Potassium terf-butoxide (0.7 g, 0.006 mol) is added to a stirred solution of 2-methoxy ethanol (0.43 mL, 0.005 mol) in dimethyl sulfoxide (10 mL) at room temperature and stirred for 5 minutes.
  • a solution of 4-chloro-8-cyclohexylmethoxy-2-methyl quinoline (1.2 g, 0.004 mol) in dimethyl sulfoxide (10 mL) is added to the reaction mixture at room temperature and then heated at 60°C for 30 minutes. Reaction mixture is cooled 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously.
  • Step IV Preparation of (R)-3- ⁇ [8-cyclohexyImethoxy-4-(2-methoxy ethoxy) quinoIin-2-ylmethyI]amino ⁇ piperidine-l-carboxylic acid tert-butyl ester.
  • Glacial acetic acid (0.04 mL, 0.0006 mol) followed by (R)-3-amino piperidine-1- carboxylic acid tert-butyl ester (0.3 g, 0.002 mol) is added to a stirred solution of 8- cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carbaldehyde (0.52 g, 0.002 mol) in dichloromethane (20 mL) at room temperature and stirred for 1 hr.
  • Sodium cyanoborohydride (0.19 g, 0.003 mol) is added to the reaction mixture at room temperature and then stirred for 2 hrs. Reaction mixture is quenched with D. M.
  • Step V Preparation of (R)-3- ⁇ [8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinolin-2-yl methyl] isopropylamino ⁇ piperidine-l-carboxylic acid tert-butyl ester.
  • Glacial acetic acid (0.04 mL, 0.0006 mol) followed by acetone (0.52 mL) is added to a stirred solution of (R)-3- ⁇ [8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinolin-2- ylmethyl]amino ⁇ piperidine-l-carboxylic acid tert-butyl ester (0.26 g, 0.0005 mol) in dichloromethane (10 mL) at room temperature and stirred for 1 hr. Sodium cyanoborohydride (0.06 g, 0.001 mol) is added to the reaction mixture at room temperature and then stirred for 2 hrs. Reaction mixture is concentrated under reduced pressure at 45°C, D.
  • Step VI Preparation of [8-cyclohexylmethoxy-4-(2-methoxyethoxy)quinolin-2-yl methyl]isopropyl-(R)-piperidin-3-yl amine trihydrochloride.
  • Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish [8-cyclohexylmethoxy-4-(2- methoxy ethoxy) quinolin-2-ylmethyl] isopropyl-(R)-piperidin-3-yl amine trihydrochloride.
  • Examples 123 and 124 are prepared according to the similar procedure as described in Example 122, using appropriate starting material and reagents.
  • Step I Preparation of 4-chloro-8-cyclopentylmethoxy-2-methyl quinoline.
  • N,N-Di-isopropylethylamine (1.8 mL, 0.01 1 mol) is added to a stirred solution of cyclopentylmethanol (0.7 g, 0.007 mol) in dichloromethane (10 mL) at room temperature and stirred for 5 minutes. Reaction mixture is cooled to 0-5°C, methanesulphonylchloride (0.65 mL, 0.008 mol) is added dropwise to the reaction mixture and stirred for 30 minutes. D. M. water (10 mL) is added to the reaction mixture, organic layer is separated and aqueous layer is extracted with dichloromethane (2x20 mL). Combined organic layer is washed with D. M.
  • Potassium carbonate (1.5 g, 0.011 mol) is added to a stirred solution of 4-chloro-2- methyl quinolin-8-ol (1.05 g, 0.005 mol) in N,N-dimethylformamide (8 mL) at room temperature and stirred for 15' minutes.
  • a solution of methanesulfonic acid cyclopentylmethyl ester (1.25 g, 0.007 mol) in ⁇ , ⁇ -dimethyl formamide (7 mL) is added to the reaction mixture and then heated at 90°C for 5 hrs. Reaction mixture is cooled to 10-15°C, D. M. water (25 mL) is added and extracted with ethyl acetate (3x30 mL).
  • Step II Preparation of 4-chloro-8-cyclopentylmethoxy quinoline-2- carbaldehyde.
  • Selenium dioxide 0.5 g, 0.004 mol
  • 4-chloro-8- cyclopentylmethoxy-2-methyl quinoline (1.05 g, 0.004 mol)
  • 1 ,4-dioxane 15 mL
  • Reaction mixture is cooled to room temperature, filtered through celite bed and washed with 1 ,4-dioxane (3x20 mL).
  • Step III Preparation of 4-chIoro-8-cyclopentylmethoxy quinoline-2-carboxylic acid.
  • An aqueous solution (8 mL) containing sodium chlorite (0.67 g, 0.006 mol, 80%) and sodium dihydrogen orthophosphate dihydrate (1.87 g, 0.012 mol) is added to a heterogeneous solution of 4-chloro-8-cyclopentylmethoxy quinoline-2-carbaldehyde (0.58 g, 0.002 mol) in tert-butanol (15 mL) at room temperature and stirred for 2 hrs.
  • Dichloromethane 25 mL followed by D.M.
  • Step IV Preparation of (R)-3-[(4-chloro-8-cyclopentylmethoxy quinoline-2- carbonyI)isopropylamino]piperidine-l-carboxylic acid ter/-butyl ester.
  • Oxalyl chloride (0.32 mL, 0.004 mol) is added dropwise to a stirred solution of 4- chloro-8-cyclopentylmethoxy quinoline-2-carboxylic acid (0.54 g, 0.002 mol) in dichloro methane (20 mL) at room temperature.
  • N,N-Dimethylformamide (0.02 mL, 0.0003 mol) is added to the reaction mixture and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 40°C to get acid chloride derivative, which is directly used for the next step.
  • Step V Preparation of (R)-3- ⁇ [4-(2-acetyIamino ethylsulfanyl)-8-cyclopentyl methoxy quinoline-2-carbonyl]isopropylamino ⁇ piperidine-l-carboxyIic acid tert- butyl ester. Potassium tert-butoxide (0.09 g, 0.0008 mol) is added to a stirred solution of N-(2- mercaptoethyl) acetamide (0.09 g, 0.0008 mol) in dimethylsulfoxide (3 mL) at room temperature and stirred for 10 minutes.
  • Step VI Preparation of 4-(2-acetylaminoethylsulfanyl)-8-cyclopentylmethoxy quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide dihydrochloride.
  • Step I Preparation of l-nitro-2-prop-2-ynyloxy benzene.
  • Potassium carbonate (19.8 g, 0.144 mol) is added to a stirred solution of 2-nitro phenol (10.0 g, 0.071 mol) in N,N-dimethylformamide (100 mL) at room temperature and stirred for 15 minutes.
  • Propargyl bromide (10.4 mL, 0.093 mol) is added to the reaction mixture and then heated at 65°C for 30 minutes. Reaction mixture is cooled to room temperature, filtered to remove potassium carbonate and then washed with ethyl acetate (2x50 mL).
  • D. M. water 100 mL is added to the combined filtrate, organic layer is separated and aqueous layer is extracted with ethyl acetate (2x100 mL).
  • Step III Preparation of 2-methyl benzofuran-7-ylamine.
  • Step IV Preparation of 6-h droxy-2-methyl furo[3,2-h]quinoline-8-carboxylic acid methyl ester.
  • Dimethyl acetylenedicarboxylate (2.33 mL, 0.019 mol) is added to a solution of 2- methyl benzofuran-7-ylamine (2.8 g, 0.019 mol) in methanol (42 mL) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 50°C, the resulting liquid is added dropwise to a pre-heated solution of diphenyl ether (23 mL) at 250°C and then heating is continued for 15 minutes. Reaction mixture is cooled to room temperature, petroleum ether (40 mL) is added to it and stirred for 10 minutes.
  • Petroleum ether layer is decanted and the crude material is purified by column chromatography (silica gel 230-400 mesh, dichloromethane:methanol, 98:2) to get 6-hydroxy-2 -methyl furo[3,2-h]quinoline-8- carboxylic acid methyl ester.
  • Step V Preparation of 6-chloro-2-methy! furo[3,2-h]quinoline-8-carboxylic acid methyl ester.
  • Step VII Preparation of (R)-3-[(6-chloro-2-methyl furo[3,2-h]quinoline-8- carbonyl)isopropylamino]piperidine-l-carboxylic acid ter/-butyl ester.
  • Oxalyl chloride (0.3 mL, 0.003 mol) is added dropwise to a stirred solution of 6- chloro-2-methyl furo[3,2-h]quinoline-8-carboxylic acid (0.45 g, 0.002 mol) in dichloromethane (10 mL) at room temperature.
  • N,N-Dimethylformamide (0.02 mL, 0.0003 mol) is added to the reaction mixture and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 40°C to get acid chloride derivative, which is directly used for the next step.
  • Step VIII Preparation of (R)-3- ⁇ isopropyI-[6-(2-methoxy ethoxy)-2-methyl furo
  • Potassium tert-butoxide (0.08 g, 0.0007 mol) is added to a stirred solution of 2- methoxy ethanol (0.05 mL, 0.0007 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 5 minutes.
  • a solution of (R)-3-[(6-chloro-2-methyl furo[3,2-h]quinoline-8-carbonyl)isopropylamino]piperidine-l-carboxylic acid tert- butyl ester (0.25 g, 0.0005 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr.
  • Reaction mixture is cooled to 10- 15°C, ethyl acetate (25 mL) followed by D. M. water (12 mL) is added to the reaction mixture and stirred vigorously for 5 minutes.
  • Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x25 mL). Combined organic layer is washed with D. M. water (1x20 mL) followed by brine solution (1x20 mL) and dried over anhydrous sodium sulphate.
  • Step IX Preparation of 6-(2-methoxy ethoxy)-2-methyl furo[3,2-h]quinoline-8- carboxylic acid isopropyI-(R)-piperidin -3-yl amide dihydrochloride.
  • a solution of 4M hydrochloric acid in 1,4-dioxane (0.9 mL) is added to (R)-3- ⁇ isopropyl-[6-(2-methoxy ethoxy)-2-methyl furo[3,2-h]quinoline-8-carbonyl]amino ⁇ piperidine-l-carboxylic acid teri-butyl ester (0.16 g, 0.0003 mol) at room temperature and stirred for 30 minutes.
  • Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane:methanol mixture(50:50, 2 mL) and again concentrated under reduced pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane:methanol mixture(50:50, 2 mL), concentrated and dried under reduced pressure to furnish 6-(2-methoxy ethoxy)-2-methyl furo[3,2-h] quinoline-8-carboxylic acid isopropyl-(R)-piperidin -3-yl amide dihydrochloride. Examples 131-133 are prepared according to the similar procedure as described in Example 130, using appropriate starting material and reagent.
  • Step I Preparation of (S)-3-[(4-chIoro-8-cycIohexylmethoxyquinoline-2- carbonyl)-isopropylamino]pyrrolidine-l-carboxylic acid tert-butyl ester.
  • Step II Preparation of (S)-3- ⁇ [8-cycIohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isopropylamino ⁇ pyrrolidine-l-carboxylic acid tert-butyl ester.
  • Potassium tert-butoxide (0.1 1 g, 0.001 mol) is added to a stirred solution of 2- methoxy ethanol (0.07 mL, 0.0009 mol) in dimethyl sulfoxide (3 mL) at room temperature and stirred for 10 minutes.
  • a solution of (S)-3-[(4-chloro-8- cyclohexylmethoxy quinoline-2-carbonyl)isopropylamino]pyrrolidine-l -carboxylic acid tert-butyl ester (0.39 g, 0.0007 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr.
  • Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted With ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate.
  • Step III Preparation of 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2- ; carboxylic acid isopropyI-(S)-pyrrolidin-3-yl amide dihydrochloride.
  • Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide dihydrochloride.
  • Examples 135-145 are prepared according to the similar procedure as described in Example 134, using appropriate starting material and reagent.
  • Step I Preparation of (R)-3-[(4-chloro-8-cycIohexylmethoxy quinoIine-2- carbonyl) isobutylamino] piperidine-l-carboxylic acid tert-butyl ester.
  • Thionyl chloride (0.2 mL, 0.003 mol) is added dropwise to a stirred solution of 4- chloro-8-cyclohexylmethoxy quinoline-2-carboxylic acid (0.3 g, 0.0009 mol) in dichloromethane (10 mL) at room temperature.
  • N,N-Dimethylformamide (0.01 mL, 0.0002 mol) is added to the reaction mixture and heated at 60°C for 1 hr. Reaction mixture is concentrated under reduced pressure at 40°C to get the acid chloride derivative, which is directly used for the next step.
  • Step II Preparation of (R)-3- ⁇ [8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isobutylamino ⁇ piperidine-l-carboxylic acid tert-buty ⁇ ester.
  • Potassium tert-butoxide (0.08 g, 0.0007 mol) is added to a stirred solution of 2- methoxy ethanol (0.06 mL, 0.0008 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 10 minutes.
  • a solution of (R)-3-[(4-chloro-8- cyclohexylmethoxy quinoline-2-carbonyl)isobutylamino]piperidine- 1 -carboxylic acid tert-butyl ester (0.32 g, 0.0006 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr.
  • Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate.
  • Step III Preparation of 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isobutyl-(R)-piperidin-3-yl amide dihydrochloride.
  • Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8- cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isobutyl-(R)- piperidin-3-yl amide dihydrochloride.
  • Examples 147-149 are prepared according to the similar procedure as described in Example 146, using appropriate starting material and reagents. Table 6:

Abstract

A compound of formula (I), formula (I) or pharmaceutically acceptable salt thereof, as renin inhibitor, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of cardiovascular disorders related to hypertension, in warm-blooded animals. Further the present invention also provides a method for treatment of disorders like congestive heart failure, cardiac hypertrophy, cardiac fibrosis, coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism etc.

Description

QUINOLINE DERIVATIVES AS RENIN INHIBITORS
RELATED APPLICATIONS
This application claims the benefit of Indian Patent Application No. 3177/MUM/201 1 filed on November. 11, 201 1 which is hereby incorporated by reference. FIELD OF INVENTION
The present invention relates to novel quinoline derivatives as renin inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of cardiovascular disorders related to hypertension, in warm-blooded animals. Further the present invention also provides a method for treatment of disorders like congestive heart failure, cardiac hypertrophy, cardiac fibrosis, coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism etc. BACKGROUND OF THE INVENTION
Hypertension is one of the major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death worldwide. Inhibitors of the renin-angiotensin systems (RAS) are known to be successful treatments for hypertension. As renin specifically catalyses the rate- limiting step of the RAS, it represents the optimal target for RAS inhibition.
Several peptide-like renin inhibitors have been reported earlier but due to their poor pharmacokinetic properties (poor absorption and rapid elimination) these compounds were not clinically useful. The development of oral renin inhibitors thus met with several challenges. The clinical development of aliskiren was a significant breakthrough for this class of compounds. However, there still exist a need to develop renin inhibitors with improved oral bioavailability, specificity for human renin, efficacy and good pharmacokinetic properties.
The first non-peptide renin inhibitors with high in vitro activity have been reported in PCT application WO 1997/00931 1. Amine based non-peptidic renin inhibitors have been disclosed in WO2007/099509. The quinoline derivatives disclosed in JP2010- 163361 (WO2008/136457) and JP2010-208947 are not considered to be the part of the present invention.
The present invention relates novel quinoline derivatives as renin inhibitors.
SUMMARY OF THE INVENTION
The present invention relates to compounds of formula (I),
Figure imgf000003_0001
formula (I)
or pharmaceutically acceptable salt thereof, wherein; X is selected from O or S;
Y is bond or a group selected from O or NH, with the proviso that Y is NH when X is S;
Z is a group selected from -CO, -C¾ -CH2CO, -C=NH;
R is selected from the group consisting of substituted or unsubstituted -Ci-5-linear or branched alkyl, -C3_8-cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with C 1.3 -linear or branched alkyl group; R is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-C1-8-alkyl, -(CH2)qO-C3- 12-cycloalkyl, -(CH2)qCO-C,.8-alkyl, -(CH2)qCO-C3- 12-cycloalkyl, -(CH2)qCO-aryl, - COd.8-alkyl, -COC3.,2-cycloalkyl, -CO-aryl, -COOC,.8-alkyl, -COOC3-12-cycloalkyl, -S02C).8-alkyl, -S02-aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical, and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -Ci-i2-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-Ci.8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C,-8-alkyl, -(CH2)qCO-C3.12-cycloalkyl, - (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COC,.8-alkyl, -COC3-,2-cycloalkyl, -CO- aryl, -COOCi-8-alkyl, -COOC3.i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6, with proviso that R2 is -C7-i2-linear or branched alkyl when Z is -CO;
R3 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted -Ci-8-alkyl, -C3-i2-cycloalkyl; or OR2 and R3 together with the carbon atom to which they are attached form a 3 to 6-
membered cyclic ring system, ring 'c' of the formula
Figure imgf000004_0001
one or more double bond, R" is a substitutent selected from -Ci-8-alkyl cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
'n' is an integer selected from 0, 1 and 2;
'mi ', 'm2' and 'm3' are integers independently selected from 0, 1, 2, 3 and 4; ( * ) at the ring carbon, indicate (R) or (S configuration or a racemate (RS). One aspect of the present invention relates to compounds of formula (la),
Figure imgf000005_0001
formula (la)
or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C3.12-cycloa.kyl, cycloalkylalkyl, -(CH^qO-Q.s-alkyl, ~(CH2)qCO -C| -8-alkyI, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COCi-g-alkyl, -COC3.]2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7-i2-linear or branched alkyl, -(CH2)q-C3.i2-cycloalkyl, -(CH2)qO-C,.8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-Ci.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COCi.8-alkyl, -COC3.i2-cycloalkyl, -CO- aryl, -COOCi.8-alkyl, -COOC3.i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6; V is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (5) configuration or racemate (RS . Another aspect of the present invention relates to compounds of formula (lb),
Figure imgf000006_0001
formula (lb) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O); 'λ
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alk l, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, - -(CH2)qCO- Ci-8-alkyI, -(CH2)qCO-C3.i2-cycloalkyl, -(CH2)qCO-aryl, -COCi.8-alk l, -COC3.,2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -(CH2)q-C3.,2-cycloalkyl -, -(CH2)qO-C1-8-alkyl, -(CH2)qO-C3-]2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-Ci-8-alkyl, -(CH2)qCO-C3-,2-cycloalkyl, - (CH2)qCO-aryl, -COCi-8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC1-8-alkyl, - COOC3.i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS). Another aspect of the present invention relates to compounds of formula (Ic),
Figure imgf000007_0001
formula (Ic) or pharmaceutically acceptable salt thereof, wherein; R1 is selected from the group consisting of substituted or unsubstituted -Ci.8-linear or branched alkyl, -C3.i2-cycloalky[, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- C,.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COC,.8-alkyl, -COC3.12- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3.i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6; 1
R2 is selected from the group consisting of substituted or unsubstituted -C1-8-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3.,2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-Ci-8-alkyl, -(CH2)qCO-C3.,2-cycloalkyl, - (CH2)qCO-aryl, -COC1-8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOCi.8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2; ( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS). Another aspect of the present invention relates to compounds of formula (Id),
Figure imgf000008_0001
formula (Id) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O); 1
R1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-C,-8-alkyl, ~(CH2)qCO- Ci_8-alkyl, -(CH2)qCO-C3.i2-cycloalkyl, -(CH2)qCO-aryl, -COCi-8-alkyl, -COC3-12- cycloalkyl, -CO-aryl, -COOC,.8-alkyl, -COOC3.I2-cycloalkyl, -S02C,.8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
Figure imgf000009_0001
ring 'c' of the formula (R")p , contains optionally one or more double bond;
R" is a substituted selected from -Ci.g-alkyl or -C3.i2-cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
'n' is an integer selected from 0, 1 and 2; ( * ) at the piperidin-3-yl carbon, indicate (R) or (5) configuration or racemate (RS). Another aspect of the present invention relates to compounds of formula (Ie),
Figure imgf000009_0002
formula (Ie) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci.8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci.8-alkyl, ~(CH2)qCO- Ci-s-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COC,-8-alkyl, -COC3-i2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02C1-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6; 2
R is selected from the group consisting of substituted or unsubstituted -C7-i2-linear or branched alkyl, - -(CH2)q-C3-i2-cycloalkyl ~(CH2)qO-C1-8-alkyl, -(CH2)qO-C3-12- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-12-cycloalkyl, - (CH2)qCO-aryl, -COd.g-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC,.8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
'mi ', 'm2' and 'm3' are integers independently selected from 0, 1, 2, 3 and 4; ( * ) at the ring carbon indicate (R) or (S) configuration or racemate (RS).
Another aspect of the present invention relates to compounds of formula (If),
Figure imgf000010_0001
formula (If) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R is selected from the group consisting of substituted or unsubstituted -Ci-5-linear or branched alkyl, -C3.8-cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci-3-linear or branched alkyl group; R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-C1-8-alkyl, ~(CH2)qCO- C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COC1-g-alkyl, -COC3.12- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci.8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7.i2-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl,
Figure imgf000011_0001
-(CH2)qCO-C3.12-cycloalkyl, - (CH2)qCO-aryl, -COC1-8-alkyl, -COC3-,2-cycloalkyl, -CO-aryl, -COOCi-8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6; 'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (i?) or (5) configuration or racemate (RS).
The invention also provides the use of compound of formula (la-If) or salt or N- oxides thereof for the preparation of pharmaceutical composition comprising compound of formula (la-If) or N-oxide thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof.
Further the present invention also provides a method for treatment of disorders like hypertension as well as congestive heart failure, cardiac hypertrophy, cardiac fibrosis coronary artery disease, vasculopathy, neuropathy, intraocular hypertension, glaucoma, diabetic nephropathy, abnormal vascular growth, hyperaldosteronism comprising administering to a mammal in need of such treatment an effective amount of compound of formula (Ia-If) or salt or N-oxides thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compounds of formula (I),
Figure imgf000012_0001
formula (I) or pharmaceutically acceptable salt thereof, wherein; X is selected from O or S;
Y is bond or a group selected from O or NH, with the proviso that Y is NH when X is S;
Z is a group selected from -CO, -CH2, -CH2CO , -C=NH;
R is selected from the group consisting of substituted or unsubstituted -Ci.s-linear or branched alkyl, -C3-8-cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci-3 -linear or branched alkyl group;
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3- 12-cycloalkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, - COQ.g-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC1-8-alkyl, -COOC3-)2-cycloalkyl, -S02Ci_8-alkyl, -S02-aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical, and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R is selected from the group consisting of substituted or unsubstituted -Ci-i2-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3.12- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -. (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COCi-8-alkyl, -COC3-i2-cycloalkyl, -CO- aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6, with proviso that R2 is -C7-i2-alkyl when Z is -CO,;
R3 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted -Ci-8-alkyl, -C3-i2-cycloalkyl; or OR2 and R3 together with the carbon atom to which they are attached form a 3 to 6-
Figure imgf000013_0001
membered cyclic ring system, ring 'c' of the formula (R ')p , with optional one or more double bond, R" is a substitutent selected from -Ci-8-alkyl or -C3_i2- cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
'n' is an integer selected from 0, 1 and 2;
'mi ', 'm2' and 'm ' are integers independently selected from 0, 1, 2, 3 and 4; ( * ) at the ring carbon, indicate (R) or (5) configuration or a racemate (RS).
According to one embodiment, specifically provided are compounds of the formula (la),
Figure imgf000014_0001
formula (la) or pharmaceutically acceptable salt thereof,
wherein; Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- C1-8-alkyl, -(CH2)qCO-C3-,2-cycloalkyl, -(CH2)qCO-aryl, -COC1-8-alkyl, -COC3.i 2- cycloalkyl, -CO-aryl, -COOC!-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7.]2-linear or branched alkyl, -(CH2)q-C3.i2-cycloalkyl, -(CH2)qO-Ci.8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C,.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COC1-8-alkyl, -COC3.i2-cycloalkyl, -CO- aryl, -COOCi-8-alkyl, -COOC3-]2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2; ( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS).
According to one embodiment, specifically provided are compounds of the formula (la) in which Y is O.
According to another embodiment, specifically provided are compounds of the formula (la) in which 'n' is 1.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which Rl is -Ci-8-linear or branched alkyl group selected from methyl, ethyl, rc-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R1 is -COOCi-8-alkyl, wherein -Ci-8-alkyl group selected from methyl, ethyl, ^-propyl, isopropyl, -butyl, isobutyl, and 1 , 1 -dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R1 is cycloalkylalkyl, selected from cyclopropylmethyl, cyclobutylethyl and cyclopentylethyl.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R1 is -CH20-Ci-8-alkyl, wherein -Ci-8-alkyl selected from methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, and 1 ,1-dimethylethyl (t-butyl). According to yet another embodiment, specifically provided are compounds of the formula (la) in which, 'n' is 0, Y is absent and R1 is substituted aryl selected from phenyl substituted with alkoxy, halogen, or haloalkyl group.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which, R2 is substituted or unsubstituted -C7-i2-linear or branched alkyl group selected from heptyl, octyl, nonyl, decyl etc. According to yet another embodiment, specifically provided are compounds of the formula (la) in which, R2 is -(CH2)q-C3-i2-cycloalkyl ring selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6. According to yet another embodiment, specifically provided are compounds of the formula (la) in which, R2 is -(CH2)q-C4-i2-heterocyclic ring containing heteroatom oxygen or nitrogen, selected from tetrahydrofuran-2-ylmethyl, tetrahydropyran-4- ylmethyl, tetrahydrofuran-3-yl, oxetan, piperidine, pyrrolidine etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6. According to yet another embodiment, specifically provided are compounds of the formula (la) in which, R2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci-s-alkyl, halogen, trifluormethyl and -C3.i2-cycloalkyl etc.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which, R2 is aryl or heteroaryl group selected from pyridine-2- ylmethyl, pyridine-3-ylmethyl and indan-2-yl.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -CH20-Ci.8-alkyl, wherein -Ci-8-alkyl selected from methyl, ethyl, n-propyl, isopropyl, «-butyl, isobutyl, and 1,1-dimethylethyl (t-butyl). According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -CH2CO-Ci.8-alkyl, wherein -Ci.g-alkyl selected from methyl, ethyl, «-propyl, isopropyl, «-butyl, isobutyl, and 1,1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -CH2CO-C3_i2-cycloalkyl, wherein the -C3_i2-cycloalkyl group is selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantan-l-yl. According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -CH2CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -Ci-8-alkyl, halogen, trifluormethyl and -C3.i2-cycloalkyl. According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is - (CH2)qCOheteroaryl„ wherein the heteroaryl group oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolinyl, isoquinolinyl, thiadiazolyl, indolizinyl, acridinyl, phenazinyl, imidazo[ l ,2-a]pyridyl, imidazo[l,2- ajpyridine and phthalazinyl and and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -COCi-8-alkyl, wherein -Ci-8-alkyl selected from methyl, ethyl, ^-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -COC3.i2-cycloalkyl, wherein the -C3.i2-cycloalkyl group is selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantan-l-yl.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which R2 is -CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -Ci-8-alkyl, halogen, trifluormethyl and -C3-i2-cycloalkyl. According to yet another embodiment, specifically provided are compounds of the formula (la) in which R is -COOCj.g-alkyl, wherein -Ci.g-alkyl selected from methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the \ formula (la) in which the configuration at the chiral centre ( * ) is R.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which the configuration at the chiral centre ( * ) is S.
According to one embodiment, specifically provided are compounds of formula (lb),
Figure imgf000018_0001
' formula (lb) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3.i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, - -(CH2)qCO- C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COQ.g-alkyl, -COCM2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02C!-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6; 2
R is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3.I2- cycloalkyl, -(CH2)qO-aralkyl,
Figure imgf000019_0001
-(CH2)qCO-C3.,2-cycloalkyl, - (CH2)qCO-aryl, -COC1-8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC,.8-alkyl, - COOC3- ]2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (5) configuration or racemate (RS). According to another embodiment, specifically provided are compounds of the formula (lb) in which Y is O.
According to yet another embodiment, specifically provided are compounds of the formula (lb) in which 'n' is 1.
According to yet another embodiment, specifically provided are compounds of the formula (lb) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (lb) in which R1 is -Ci-8-linear or branched alkyl group selected from methyl, ethyl, «-propyl, isopropyl, rc-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (lb) in which, R2 is -(CH2)q-C3.]2-cycloalkyl ring which may contain one or more heteroatom selected from oxygen, nitrogen and sulphur and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (lb) in which the configuration at the chiral centre ( * ) is R. According to another embodiment, specifically provided are compounds of the formula (Ic),
Figure imgf000020_0001
formula (Ic) or pharmaceutically acceptable salt thereof, wherein;
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-12-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- Ci.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COC,.8-alkyl, -COC3-12- cycloalkyl, -CO-aryl, -COOCi.8-alkyl, -COOC3-i2-cycloalkyl, -S02C]-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6; R2 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -(CH2)q-C3.,2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3.12- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C,.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, -COCU8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOd.8-alkyl, - COOC3.i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2; ( * ) at the piperidin-3-yl carbon, indicate (R) or (8) configuration or racemate (RS).
According to one another embodiment, specifically provided are compounds of the formula (Ic) in which 'n' is 1.
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which R1 is -COC1-8-alkyl, wherein -Ci-8-alkyl selected from methyl, ethyl, tt-propyl, isopropyl, w-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which R1 is -S02Ci-8-alkyl, wherein -C i-8-alkyl selected from methyl, ethyl, «-propyl, isopropyl, rc-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which R1 is -CO-aryl, wherein the aryl group is phenyl optionally substituted with one or more substituent selected from -C1-8-alkyl, halogen, trifluormethyl and -C3.i2-cycloalkyl.
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which, R2 is substituted or unsubstituted -C).8-alkyl, selected from methyl, ethyl, n-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which, R2 is -(CH2)q-C3.i2-cycloalkyl ring which may contain one or more heteroatom selected from oxygen, nitrogen and sulphur and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which, R2 is aralkyl, selected from benzyl or phenethyl optionally substituted with one or more substituent selected from -Ci-8-alkyl, halogen, trifluormethyl and -C3.i2-cycloalkyl etc. According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which the configuration at the chiral centre ( * ) is R.
According to one embodiment, specifically provided are compounds of the formula (Id),
Figure imgf000022_0001
formula (Id) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O); R1 is selected from the group consisting of substituted or unsubstituted -Ci.g-linear or branched alkyl, -C3.i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-g-alkyl, --(CH2)qCO- Ci-s-alkyl, -(CH2)qCO-C3-12-cycloalkyl, -(CH2)qCO-aryl, -COCi-8-alkyl, -COC3-i2- cycloalkyl, -CO-aryl, -COOCi.8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyi, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
ring 'c' of the formula
Figure imgf000022_0002
, contains optionally one or more double bond;
R" is a substitutent selected from -Ci-8-alkyl or -C3-i2-cycloalkyI and 'p' is an integer selected from 0, 1 or 2; 'η' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (5) configuration or racemate (RS).
According to another embodiment, specifically provided are compounds of the formula (Id) in which Y is O. According to yet another embodiment, specifically provided are compounds of the formula (Id) in which 'n' is 1.
According to yet another embodiment, specifically provided are compounds of the formula (Id) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (Id) in which R1 is -Ci-s-linear or branched alkyl group selected from methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the
formula (Id) in which ring 'c'of the formula
Figure imgf000023_0001
is 5-membered furan ring. According to yet another embodiment, specifically provided are compounds of the formula (Id) in which ring 'c' is 5-membered furan ring optionally containing a double bond.
According to yet another embodiment, specifically provided are compounds of the formula (Id) in which ring 'c' is 5-membered furan ring is substituted with one or more methyl group i.e. R" is a methyl group and 'p' is 1 or 2.
According to yet another embodiment, specifically provided are compounds of the formula (Id) in which the configuration at the chiral centre ( * ) is R. According to another embodiment, specifically provided are compounds of the formula (Ie),
Figure imgf000024_0001
formula (Ie) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, --(CH2)qCO- Ci-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COCi.8-alkyl, -COC3-i2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-,2-cycloalkyl, -S02C1-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6; R2 is selected from the group consisting of substituted or unsubstituted -C7.i2-linear or branched alkyl, -(CH2)q-C3.i2-cycloalkyl ring ~(CH2)qO-Ci.8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-Ci-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, -COC1-8-alkyl, -COC3-12-cycloalkyl, -CO-aryl, -COOCi-8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2; 'mi ', 'm2' and 'm3' are integers independently selected from 0, 1, 2, 3 and 4;
( * ) at the ring carbon indicate (R) or (S) configuration or racemate (RS).
According to another embodiment, specifically provided are compounds of the formula (Ie) in which 'n' is 1. According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which R1 is -Ci.g-linear or branched alkyl group, selected from methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, and 1, 1-dimethylethyl (/-butyl). According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which, R2 is -(CH2)q-C3-i2-cycloalkyl ring selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which, R2 is -(CH2)q-C4_i2-heterocyclic ring containing heteroatom oxygen or nitrogen, selected from tetrahydrofuran-2-ylmethyl, tetrahydropyran-4- ylmethyl, tetrahydrofuran-3-yl, oxetan, piperidine, pyrrolidine etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which R2 is -CH2CO-Ci-8-alkyl, wherein -C]-8-alkyl selected from methyl, ethyl, ^-propyl, isopropyl, «-butyl, isobutyl, and 1 ,1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which, 'mi ' is 0 or 1.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which, 'm2' is an integer selected from 1 , 2, 3 or 4. According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which, 'm3' is an integer selected from 0 or 1.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which the configuration at the chiral centre ( * ) is R. According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which the configuration at the chiral centre ( * ) is S.
According to yet another embodiment, specifically provided are compounds of the formula (Ie) in which the configuration at the chiral centre ( * ) is RS.
According to another embodiment, specifically provided are compounds of the formula (If),
Figure imgf000026_0001
formula (If) or pharmaceutically acceptable salt thereof, wherein;
Y is bond or oxygen (O);
R is selected from the group consisting of substituted or unsubstituted -Ci.s-linear or branched alkyl, -C3.8-cycloalkyl and cycloalkylalkyl; wherein cyeloalkyl group may be optionally substituted with Ci-3-linear or branched alkyl group; R1 is selected from the group consisting of substituted or unsubstituted -Ci.8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, ~(CH2)qCO- C.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COCi-8-alkyl, -COC3-12- cycloalkyl, -CO-aryl, -COOC]-8-alkyl, -COOC3.i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloaikyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7-i2-linear or branched alkyl, -(CH2)q-C3.]2-cycloalkyl -, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-12-cycloalkyl, - (CH2)qCO-aryl, -COCi-8-alkyl, -COC3-12-cycloalkyl, -CO-aryl, -COOCi-8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloaikyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS). According to another embodiment, specifically provided are compounds of the formula (If) in which Ύ' is O.
According to yet another embodiment, specifically provided are compounds of the formula (If) in which R is -C[.8-linear or branched alkyl group, selected from methyl, ethyl, rt-propyl, isopropyl, M-butyl, isobutyl, and 1 , 1-dimethylethyl (i-butyl). According to yet another embodiment, specifically provided are compounds of the formula (If) in which R is -C3-g-cycloalkyl, selected from cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
According to yet another embodiment, specifically provided are compounds of the formula (If) in which 'n' is 1. According to yet another embodiment, specifically provided are compounds of the formula (If) in which 'n' is 2.
According to yet another embodiment, specifically provided are compounds of the formula (If) in which R1 is -Ci-8-alkyl group selected from methyl, ethyl, w-propyl, isopropyl, w-butyl, isobutyl, and 1, 1-dimethylethyl (/-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (If) in which, R2 is -(CH2)q-C3.i2-cycloalkyl ring with the total number of carbon atom is more than six, selected from cycloheptyl, cyclooctyl, cyclohexyl methyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl etc. and 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6.
According to yet another embodiment, specifically provided are compounds of the formula (If) in which R2 is -CH2CO-Ci-8-alkyl, wherein -Ci-8-alkyl selected from methyl, ethyl, rc-propyl, isopropyl, H-butyl, isobutyl, and 1 , 1-dimethylethyl (t-butyl).
According to yet another embodiment, specifically provided are compounds of the formula (If) in which the configuration at the chiral centre ( * ) is R .
The following are definitions of the terms used in this specification. The initial definition provided for a group or term herein applies to that group or term throughout the present specification, individually or as part of another group, unless otherwise indicated.
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated.
The term "alkyl" refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, either linear or branched, having from one to eight carbon atoms, both inclusive, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, «-propyl, 1-methylethyl (isopropyl), w-butyl, «-pentyl, and 1,1-dimethylethyl (t-butyl). The term "Ci-8 alkyl" refers to an alkyl chain, linear or branched having 1 to 8 carbon atoms, both inclusive. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be, substituted or unsubstituted. The term "cycloalkyl" denotes a non-aromatic mono-, or multicyclic ring system of 3 to about 12 carbon atoms. Monocyclic rings include include, but are not limited to cylcopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of simple multicyclic cycloalkyl groups include perhydronapththyl, perhydroindenyl etc; bridged multicyclic groups include adamantyl and norbornyl etc, and spriromulticyclic groups for e.g., spiro(4,4)non-2-yl. Unless set forth or recited to the contrary, all cycloalkyl groups described or claimed herein may be substituted or unsubstituted and may optionally contain one or more heteroatom selected from O, S and N.
The term "cycloalkylalkyl" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group. The cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl and cyclopentylethyl. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted and may optionally contain one or more heteroatom selected from O, S and N.
The term "alkoxy" denotes an alkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are -OCH3 and -OC2H5. Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted. The terms "halogen" or "halo" means fluorine, chlorine, bromine or iodine. Similarly, "haloalkyl" or "haloalkoxy" refers to an alkyl or alkoxy group substituted with one or more halogen atoms.
The term "aryl" refers to an aromatic radical having 6 to 14 carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems such as phenyl, naphthyl, tetrahydronapthyl, indanyl and biphenyl. Unless set forth or recited to the contrary, all aryl groups described or claimed herein may be substituted or unsubstituted.
The term "arylalkyl" refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H5 and -C2H4C6H5. Unless set forth or recited to the contrary, all arylalkyl groups described or claimed herein may be substituted or unsubstituted.
The term "heteroaryl" unless otherwise specified refers to substituted or unsubstituted 5 to 14 membered aromatic heterocyclic ring radicals with one or more heteroatom(s) independently selected from N, O or S. The heteroaryl may be a mono-, bi- or tricyclic ring system. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Examples of such heteroaryl ring radicals include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolinyl, isoquinolinyl, thiadiazolyl, indolizinyl, acridinyl, phenazinyl, imidazo[l ,2-a]pyridyl, imidazo[l,2- a]pyridine and phthalazinyl. Unless set forth or recited to the contrary, all heteroaryl groups described or claimed herein may be substituted or unsubstituted. Unless otherwise specified, the term "substituted" as used herein refers to a group or moiety having one or more of the substituents attached to the structural skeleton of the group or moiety, including, but not limited to such substituents as hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), alkyl, haloalkoxy, alkenyl, alkynyl, aryl, atylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, heteroaryl, heterocyclylalkyl ring, heteroarylalkyl, heterocyclic ring, guanidine, alkylguanidine, -COORx, -C(0)Rx, -C(S)RX, -C(0)NRxRy, - (O)ONRxRy, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)S02Ry, -(=N-N(Rx)Ry), - NRxC(0)ORy, -NRxRy, -NRxC(0)Ry, -NRxC(S)Ry, -NRxC(S)NRyRz, - SONRxRy, -S02NRxRy, -ORx, -ORxC(0)NRyRz, -ORxC(0)ORy, -OC(0)RX, - OC(0)NRxRy, -RxNRyC(0)Rz, -RxORy, -RxC(0)ORy, -RxC(0)NRyRz, - RxC(0)Ry, -RxOC(0)Ry, -SRX, -SORx, -S02Rx, and -ON02, wherein Rx, Ry and Rz are independently selected from hydrogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, amino, alkylamino, dialkylamino, aryl, heteroaryl, heterocyclylalkyl ring, heteroarylalkyl, or substituted or unsubstituted heterocyclic ring.
As mentioned above the term "heterocyclic ring" or "heterocyclic radical" unless otherwise specified refers to substituted or unsubstituted non-aromatic 3 to 15 membered ring radical which consists of carbon atoms and from one to five hejeroatoms selected from nitrogen, phosphorus, oxygen and sulfur. The heterocyclic ring radical may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quarternized; also, unless otherwise constrained by the definition the heterocyclic ring or heterocyclyl may optionally contain one or more olefinic bond(s). Examples of such heterocyclic ring radicals include, but are not limited to azepinyl, azetidinyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholanyl, decahydroisoquinolyl, indanyl, indolinyl, isoindolinyl, isochromanyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, oxadiazolyl, 2-oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, octahydroindolyl, octahydroisoindolyl, perhydroazepinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, piperidinyl, phenothiazinyl, phenoxazinyl, quinuclidinyl, tetrahydroisquinolyl, tetrahydrofuryl, tetrahydropyranyl, thiazolinyl, thiazolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide and thiamorpholinyl sulfone. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted.
The term "heterocyclylalkyl" refers to a heterocyclic ring radical directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclylalkyl groups described or claimed herein may be substituted or unsubstituted.
With the groups of preferred compounds of formula (la), (lb), (Ic), (Id), (Ie), (If) and N-oxides thereof mentioned hereinafter, definitions of substituents from the general definitions mentioned hereinbefore may reasonably be used, e.g. to replace more general definitions with more specific definitions or especially with definitions characterized as being preferred.
Any asymmetric carbon atom may be present in the (R)-, (S)- or (Z?, ^-configuration. The compounds may thus be present as mixtures of stereoisomers or as pure stereoisomers. The invention relates also to possible tautomers of the compounds of formula (la), (lb), (Ic), (Id), (Ie) and (If).
Where the plural form is used for compounds, salts and the like, this is taken to mean also a single compound, salt or the like. Salts of compounds of formula (la), (lb), (Ic), (Id), (Ie) and (If) are the physiologically acceptable salts. Physiologically acceptable salts are particularly suitable for medical applications, due to their greater solubility in water compared with the starting or base compounds. Suitable physiologically acceptable acid addition salts of the compounds of the invention may be salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, and the like or of organic acids such as, for example, acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, citric acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartartic acid, amino acids, such as glutamic acid or aspartic acid, and the like. Examples of suitable physiologically acceptable basic salts are ammonium salts, or suitable organic amines, such as tertiary monoamines, e.g. triethylamine or tris(2-hydroxyethyl)amine etc., alkali metal salts such as sodium salts and potassium salts and alkaline earth metal salts such as magnesium salts and calcium salts. When a basic group and an acid group are present in the same molecule, a compound of formula (la), (lb), (Ic), (Id), (Ie), (If) may also form internal salts. Below are the representative compounds of the present invention, which are illustrative in nature only and are not intended to limit to the scope of the invention.
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-[(R)-(tetrahydrofuran-3-yl)oxy]quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Benzyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(tetrahydrofuran-2-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-(4-Fluorobenzyloxy)-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-[(S)-l-(tetrahydrofuran-2-yl)methoxy]quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(tetrahydropyran-4-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(3-Cyclopentylpropoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-phenethyloxyquinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-(4-Isopropyl cyclohexylmethoxy)-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-[4-(4-Chlorophenyl)cyclohexylmethoxy]-4-(2-methoxyethoxy)quirioline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(2-propylpentyloxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-(Indan-2-yloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-3-yl amide;
8-(2-Cyclohexylethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide; 8-(4-Isobutylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-(4-Isopropylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(4-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(4-Cyclohexylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Heptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-[2-(4-Fluorophenyl)ethoxy]-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(5-oxohexyloxy)quinoline-2-carboxyIic acid isopropyl-(R)- piperidin-3-yl amide;
8-Cyclooctyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(pyridin-2-ylmethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(pyridin-3-ylmethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-[2-(2-oxo pyrrolidin- 1 -yl)ethoxy]quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; ί
8-(2,2-Dimethoxyethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(2-ethoxyethoxy)quinoIine-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide; 8-Cycloheptyloxy-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Cycloheptyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-(3-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-(4-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-(3-Chlorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl - (R)-piperidin-3-yl amide; 4-(3-Methoxypropoxy)-8-(3-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-Benzyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
4-(3-Methoxypropoxy)-8-(tetrahydrofuran-2-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 4-(3-Methoxypropoxy)-8-[(R)-(tetrahydrofuran-3-yl)oxy]quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2,3-Dichlorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 4-(3-Methoxypropoxy)-8-[(S)- 1 -(tetrahydrofuran-2-yl)methoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Cyclooctyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Heptyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(3-methoxy propoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-Cycloheptyloxy-4-(3-ethoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide; Carbonic acid-2-[8-cycloheptyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester methyl ester;
Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester methyl ester;
Carbonic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester methyl ester;
Carbonic acid-2-[8-isobutoxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl)quinolin-4- yloxy]ethyl ester methyl ester; Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy] ethyl ester ethyl ester;
Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy] ethyl ester pentyl ester; Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy] ethyl ester isobutyl ester;
Carbonic acid-3-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]propyl ester methyl ester;
Carbonic acid-3-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]propyl ester methyl ester;
8-Cycloheptyloxy-4-(2-isobutoxyethoxy)quinoline-2-carboxyltc acid isopropyl-(R)- piperidin-3-yl amide;
8-Cycloheptyloxy-4-(2-propoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide; 8-Cycloheptyloxy-4-(2-cyclopropylmethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclohexyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 4-(2-Methoxyethoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Adamantan-l-yl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopropyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-[2-(4-Chlorophenyl)-2-oxoethoxy]-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-[2-Cyclopropyl-l-(2-fluoro phenyl)-2-oxo ethoxy]-4-(2-methoxy ethoxy)quinoline - 2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-[2-(3-Chloro phenyl)-2-oxo ethoxy]-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-(2-Furan-2-yl-2-oxo ethoxy)-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxy ethoxy)-8-(2-oxo-2-thiophen-2-yl ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Ethoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Ethoxyethoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl - (R)-piperidin-3-yl amide; 8-(3,3-Dimethyl-2-oxobutoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclohexyl-2-oxoethoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(3-Methoxypropoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopentyl-2-oxoethoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(3-Methoxypropoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-Cyclohexylmethoxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Isobutoxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Cycloheptyloxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Cyclopentyloxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-Cyclopentyloxy-4-(2-ethoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(3-methoxymethoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; -; 8-Cycloheptyloxy-4-(3-methoxymethoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Methoxymethoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-[(R)-2-(2,2-Dimethylpropionylamino)butoxy]-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 8-[(S)-2-(2,2-Dimethylpropionylamino)butoxy]-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-((R)-2-Methanesulfonylaminobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
Carbonic acid isobutyl ester-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)- piperidin-3-yl amide; 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-piperidin-3-yl amide;
Isobutyric acid-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(2-methoxyethoxy) quinolin-8-yl ester; 2,2-Dimethyl propionic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxy ethoxy)quinolin-8-yl ester;
Pentanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxyethoxy) quinolin-8-yl ester;
Hexanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxyethoxy) quinolin-8-yl ester;
Heptanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxyethoxy) quinolin-8-yl ester;
Octanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxyethoxy) quinolin-8-yl ester; Cyclopropanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbarnoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
Cyclopentanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
Cyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxy ethoxy)quinolin-8-yl ester;
1 -Methylcyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester; Adamantane- 1 -carboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
3- Cyclopentylpropionic acid-2-((R)-isopropyl-piperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy)quinolin-8-yl ester; 4-Fluorobenzoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2-methoxy ethoxy)quinolin-8-yl ester;
Pentanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3-methoxypropoxy) quinolin-8-yl ester;
Cyclopropanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxy propoxy)quinolin-8-yl ester;
Cyclopentanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxy propoxy)quinolin-8-yl ester;
Cyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3-methoxy propoxy)quinolin-8-yl ester; Hexanoic acid-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(3-methoxypropoxy) quinolin-8-yl ester;
4- (2-Methoxyethoxy)-8-methoxymethoxy quinoline-2 -carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Benzyloxymethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Benzyloxyethoxy)-8-cyclohexylmethoxy quinoline-2 -carboxylic acid isopropyl- (R)-piperidin-3-yl-amide; 8-Cyclohexylmethoxy-4-[2-(3,3-dimethyl-2-oxobutoxy)ethoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
Acetic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy] ethyl ester;
Isobutyric acid-2-[8-cyclohexylmethoxy-2-((R)-isopropyl piperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester;
2,2-Dimethyl propionic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropyl piperidin-3-yl carbamoyl)quinolin-4-yloxy]ethyl ester;
8-Cyclopentyloxy-4-(2-methoxybenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
8-Cyclopentyloxy-4-(2,3-dichloro benzyloxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
8-Cyclopentyloxy-4-(2-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
[8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl-(R)- piperidin-3-yl amine;
[8-Cyclopentyloxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl-(R)-piperidin -3-yl amine;
[8-Cycloheptyloxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl-(R)-piperidin -3-yl amine;
4-(2-Acetylaminoethylsulfanyl)-8-cyclopentylmethoxyquinoline-2-carboxylic acid isopropyl-(R)-piperidiri-3-yl amide; 4-(2-Acetylaminoethylsulfanyl)-8-cyclopentyloxyquinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Cyclopentyloxy-4-(2-methanesulfonylaminoethylsulfanyl)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 4-(2-Acetylaminoethylsulfanyl)-8-benzyloxyquinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Benzoylaminoethylsulfanyl)-8-cyclopentyloxyquinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl-amide;
6-(2-Methoxyethoxy)-2-methyl-furo[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)- piperidin-3-yl -amide;
6-(3-Methoxypropoxy)-2-methyl-furo[3,2-h]quinoline-8-carboxylic acid isopropyl- (R)-piperidin-3-yl amide; ;
6-(2-Methoxyethoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 6-(3-Methoxypropoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (S)-pyrrolidin-3-yl amide;
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)- pyrrolidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide; 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-l- pyrrolidin-2-ylmethyl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (S)-l -pyrrolidin-2-ylmethyl amide; 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-2-ylmethyl amide;
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-2-ylmethyl amide;
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid azetidin-3-yl isopropyl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-l -piperidin-3-ylmethyl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-l-piperidin-3-ylmethyl amide; 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-4-yl amide;
8-Cyclohexylmethoxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl piperidin-4-yl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isobutyl-(R)- piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid cyclopentyl- (R)-piperidin-3-yl amide; 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isobutyl-(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobiitoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid cyclopentyl-(R)-piperidin-3-yl amide.
The embodiment below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
In one embodiment, as depicted in schemes 1 or 2, the compounds of the formula (la) are obtained by converting compound of formula (1) to compound of formula (2) by alkylation at 8-hydroxy group of quinoline ring. Oxidation of methyl group at 2- position followed by further oxidation of carboxaldehyde derivative gives carboxylic acid derivative of formula (4). The compound of formula (4) is coupled with 3- isopropylamino piperidine-1 -carboxylic acid fert-butyl ester to get compound of formula (5). Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (6), which on removal of N-protecting group gives compound of formula (la).
Figure imgf000048_0001
Figure imgf000048_0002
Scheme 1
Alternatively, compound of the formula (la) can be prepared by following the procedure as depicted in scheme 2. Displacement of halogen at 4-position of compound of formula (2) by corresponding alkoxyalcohol derivative gives compound of formula (7). Oxidation of methyl group at 2-position followed by further oxidation of carboxaldehyde derivative gives carboxylic acid derivative of formula (9). Compound of formula (9) is coupled with 3-isopropylamino piperidine-1 -carboxylic acid tert-butyl ester to give compound of formula (6), which on removal of N- protecting group gives compound of formula (la).
Figure imgf000049_0001
Scheme 2
In another embodiment, compound of the formula (lb) can be prepared by following the procedure as depicted in scheme 3. Reductive amination between compound of formula (8) and 3-amino piperidine-l-carboxylic acid te -butyl ester gives compound of the formula (10), which upon further reductive amination with acetone gives compound of formula (1 1). Removal of N-protecting group of compound of formula (1 1) gives compound of formula (lb).
Figure imgf000049_0002
Scheme 3 In yet another embodiment, compound of the formula (Ic) can be prepared by following the procedure as depicted in scheme 4. Displacement of halogen of compound of formula (5) by corresponding mercaptoalkyl amide derivative leads to the compound of formula (12). Removal of N-protecting group of compound of formula (12) gives compound of formula (Ic).
Figure imgf000050_0001
Scheme 4
In yet another embodiment, compound of the formula (Id) can be prepared by following the procedure as depicted in scheme 5. Alkylation of o-nitrophenol followed by cyclization at high temperature gives compound of formula (16). Alternatively, Claisen rearrangement of alkylated o-nitrophenol of formula (14) followed by its cyclization gives same cyclized derivative of formula (16). Reduction of nitro group followed by reaction with dimethyl acetylene dicarboxylate leads to the formation of corresponding quinoline derivative of formula (18). Conversion of hydroxyl group to halogen derivative followed by hydrolysis of ester gives compound of formula (20). Compound of the formula (20) is coupled with 3-isopropylamino piperidine-l-carboxylic acid tert-butyl ester to give compound of formula (21). Displacement of halogen by corresponding alkoxyalcohol derivative leads to the formation of compound of formula (22). Removal of N-protecting group of compound of formula (22) gives compound of formula (Id).
Figure imgf000051_0001
Figure imgf000051_0002
In yet another embodiment, compound of the formula (Ie) can be prepared by following the procedure as depicted in scheme 6. The compound of formula (4) is coupled with N-isopropylamino derivative in which the amino group is either directly attached to N-boc protected azetidine and pyrrolidine derivatives or via a methylene group to N-boc protected azetidine, pyrrolidine and piperidine derivatives to get compound of formula (23). Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (24), which on removal of N-protecting group gives compound of formula (Ie).
Figure imgf000052_0001
Figure imgf000052_0002
Scheme 6
In yet another embodiment, compound of the formula (If) can be prepared by following the procedure as depicted in scheme 7. The compound of formula (4) is coupled with 3-alkylamino piperidine-l-carboxylic acid tert-butyl ester to get compound of formula (25). Displacement of halogen at 4-position of quinoline ring by corresponding alkoxyalcohol derivative leads to the compound of formula (26), which on removal of N-protecting group gives compound of formula (If).
Figure imgf000053_0001
Figure imgf000053_0002
EXPERIMENTAL
The following examples serve to illustrate the invention without limiting the invention in its scope. The methods of preparing some of the starting compounds used in the examples are described as reference examples.
General Method of Preparation
The compounds described herein, including compounds of general formula (la), formula (lb), formula (Ic), formula (Id), formula (Ie), and formula (If) can be prepared by techniques known to in the art, for example, through the reaction scheme depicted in Schemes 1-7. Furthermore, in the following examples, where specific acids, bases, reagents, coupling agents, solvents, etc. are mentioned, it is understood that other suitable acids, bases, reagents, coupling agents etc. may be used and are included within the scope of the present invention. Modifications to reaction conditions, for example, temperature, duration of the reaction or combinations thereof are envisioned as part of the present invention. The compounds obtained by using the general reaction scheme may be of insufficient purity. These compounds can be purified by any of the methods for purification of organic compounds known in the art, for example, crystallization or silica gel or alumina column chromatography using different solvents in suitable ratios.
Example 1 8-Cvcloheptyloxv-4-(2-methoxv ethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide dihydrochloride
Figure imgf000054_0001
Step I: Preparation of 4-chIoro-8-cycloheptyloxy-2-methyl quinoline Method-A: N,N-Di-isopropylethylamine (9.5 mL, 0.055 mol) is added to a stirred solution of cycloheptanol (4.2 g, 0.036mol) in dichloromethane (42 mL) at room temperature and stirred for 5 minutes. Reaction mixture is cooled to 0-5°C, methanesulphonylchloride (3.4 mL, 0.044 mol) is added dropwise manner to the reaction mixture and stirred for 30 minutes. D. M. water (40 mL) is added to the reaction mixture, organic layer is separated and aqueous layer is extracted with dichloromethane (2x40 mL). Combined organic layer is washed with D. M. water (1x40 mL) followed by brine solution (1x40 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure gives methanesulfonic acid cycloheptyl ester, which is used for the next step without purification. Potassium carbonate (4.7 g, 0.034 mol) is added to a stirred solution of 4-chloro-2- methyl quinolin-8-ol (3.0 g, 0.016 mol) in N,N-dimethylformamide (30 mL) at room temperature and stirred for 15 minutes. Methanesulfonic acid cycloheptyl ester (4.8 g, 0.025 mol) is added to the reaction mixture and heated at 90°C for 5 hrs. Reaction mixture is cooled to room temperature, filtered to remove potassium carbonate and then washed with ethyl acetate (2x50 mL). D. M. water (60 mL) is added to the combined filtrate, organic layer is separated and aqueous layer is extracted with ethyl acetate (2x60 mL). Combined organic layer is washed with D. M. water (1x50 mL) followed by brine solution (1x80 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 8:92) to get 4-chloro-8-cycloheptyloxy-2-methyl quinoline.
Method-B; Potassium carbonate (17.5 g, 0.126 mol) is added to a stirred solution of 4-chloro-2-methyl quinolin-8-ol (7.0 g, 0.036 mol) in N,N-dimethylformamide (105 mL) at room temperature and stirred for 15 minutes. Cycloheptyl bromide (10.4 mL, 0.076 mol) is added to the reaction mixture and then heated at 98°C for 7 hrs. Reaction mixture is cooled to room temperature, filter to remove potassium carbonate and washed with ethyl acetate (2x80 mL). Combined filtrate is concentrated under reduced pressure at 60°C to give crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 8:92) to get 4- chloro-8-cycloheptyloxy-2 -methyl quinoline.
Step II: Preparation of 4-chloro-8-cyc.ohepty.oxy quinoline-2-carbaldehyde. Selenium dioxide (1.35 g, 0.012 mol) is added to a stirred solution of 4-chloro-8- cycloheptyloxy-2 -methyl quirioline (2.8 g, 0.009 mol) in 1,4-dioxane (28 mL) at room temperature and then heated at 75°C for 40 minutes. Reaction mixture is cooled to room temperature, filtered through celite bed and washed with 1,4-dioxane (3x20 mL). Combined filtrate is concentrated under reduced pressure to get crude solid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 5:95) to furnish 4-chloro-8-cycloheptyloxy quinoline-2- carbaldehyde.
Step III: Preparation of 4-chloro-8-cycloheptyIoxy quinoline-2-carboxylic acid. An aqueous solution (50 mL) containing sodium chlorite (2.93 g, 0.026 mol, 80%) and sodium dihydrogen orthophosphate dihydrate (8.1 g, 0.052 mol) is added to a heterogeneous solution of 4-chloro-8-cycloheptyloxy quinoline-2-carbaldehyde (2.6 g, 0.009 mol) in te -butanol (50 mL) at room temperature and stirred for 1 hr. Dichloromethane (80 mL) followed by D. M. water (20 mL) is added to the reaction mixture and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with dichloromethane (2x25 mL). Combined organic layer is washed with brine solution (1x50 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure furnishes 4-chloro-8- cycloheptyloxy quinoline-2-carboxylic acid, which is directly used for the next step without further purification.
Step IV: Preparation of (R)-3-[(4-chloro-8-cycloheptyloxy quinoline-2-carbonyl)- isopropyIamino]-piperidine-l-carboxylic acid ter/-butyl ester.
Thionyl chloride (1.12 mL, 0.015 mol) is added drop wise to a stirred solution of 4- chloro-8-cycloheptyloxy quinoline-2-carboxylic acid (2.46 g, 0.008 mol) in dichloromethane (28 mL) at room temperature. N,N-Dimethylforrnamide (0.15 mL, 0.002 mol) is added to the reaction mixture and stirred for 1 hr and 45 minutes. Reaction mixture is concentrated under reduced pressure at 40°C to get the acid chloride derivative, which is directly used for the next step.
A solution of (R)-3-isopropylamino piperidine-l-carboxylic acid tert-butyl ester (1.86 g, 0.008 mol) and triethylamine (3.2 mL, 0.023 mol) in tetrahydrofuran (20 mL) is added to a stirred solution of 4-chloro-8-cycloheptyloxy quinoline-2-carbonyl chloride in tetrahydrofuran (20 mL) at room temperature and stirred for 2 hrs. Reaction mixture is quenched with D. M. water (10 mL) and concentrated under reduced pressure. Again, D. M. water (50 mL) is added to the residue and extracted with ethyl acetate (3x75 mL). Combined organic layer is washed with saturated sodium bicarbonate solution (1x50 mL) followed by D. M. water (1x50 mL) and brine solution (1x50 mL). Finally, it is dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 15:85) to furnish (R)-3-[(4-chloro-8-cycloheptyloxy quinoline-2-carbonyl)isopropylamino]piperidine- 1-carboxylic acid tert-butyl ester.
Step V: Preparation of (R)-3-{[8-cycloheptyloxy-4-(2-methoxy ethoxy)quinoline- 2-carbonyl]-isopropylamino}piperidine-l-carboxyIic acid tert-butyl ester.
Potassium tert-butoxide (0.07 g, 0.0006 mol) is added to a stirred solution of 2- methoxy ethanol (0.04 mL, 0.0006 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 10 minutes. A solution of (R)-3-[(4-chloro-8- cycloheptyloxy quinoline-2-carbonyl)isopropylamino]piperidine- 1 -carboxylic acid tert-butyl ester (0.23 g, 0.0004 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr. Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 50:50) to get (R)-3-{[8-cycloheptyloxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isopropylamino}piperidine-l-carboxylic acid tert-butyl ester.
Step VI: Preparation of 8-cycloheptyloxy-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide dihydrochloride.
A solution of 4M hydrochloric acid in 1 ,4-dioxane (0.8 mL) is added to (R)-3-{[8- cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carbonyl]isopropylamino}piperidine -1-carboxylic acid tert-butyl ester (0.17 g, 0.0003 mol) and stirred for 30 minutes at room temperature. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane (2 mL) and again concentrated under reduced - pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8- cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide dihydrochloride.
Examples 2-121 are prepared according to the similar procedure as described in Example 1 , using appropriate starting material and reagents. Table 1:
Figure imgf000058_0001
formula (la)
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
105 1 0 CH3 COCH2CH2Cyclopentyl 512.13 R
Figure imgf000062_0001
Y = Ab = Absent
Example 122
[8-Cyclohexylmethoxy-4-(2-methoxy ethoxy)quinolin-2-yl methyllisopropyl-(R)- piperidin-3-yl amine trihydrochloride
Figure imgf000062_0002
Step I: Preparation of 4-chloro-8-cyclohexylmethoxy-2-methy! quinoline. Potassium carbonate (5.84 g, 0.042 mol) is added to a stirred solution of 4-chloro-2- methyl quinolin-8-ol (2.0 g, 0.01 mol) in N,N-dimethylformamide (30 mL) at room temperature and stirred for 15 minutes. Cyclohexyl methyl bromide (3.56 mL, 0.026 mol) is added to the reaction mixture and then heated at 90°C for 3 hrs and 30 minutes. Reaction mixture is cooled to 10-15°C, D. M. water (40 mL) is added to the reaction mixture and extracted with ethyl acetate (3x60 mL). Combined organic layer is washed with brine solution (2x30 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetatern-hexane, 10:90) to get 4-chloro-8-cyclohexylmethoxy-2 -methyl quinoline.
Step II: Preparation of 8-cyclohexylmethoxy-4-(2-methoxyethoxy)-2-methyl quinoline.
Potassium terf-butoxide (0.7 g, 0.006 mol) is added to a stirred solution of 2-methoxy ethanol (0.43 mL, 0.005 mol) in dimethyl sulfoxide (10 mL) at room temperature and stirred for 5 minutes. A solution of 4-chloro-8-cyclohexylmethoxy-2-methyl quinoline (1.2 g, 0.004 mol) in dimethyl sulfoxide (10 mL) is added to the reaction mixture at room temperature and then heated at 60°C for 30 minutes. Reaction mixture is cooled 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously. Organic layer is separated and aqueous layer is extracted with ethyl acetate (3x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 60:40) to furnish 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)-2- methyl quinoline. Step III: Preparation of 8-cyclohexyImethoxy-4-(2-methoxyethoxy)quinoline-2- carbaldehyde.
Selenium dioxide (0.35 g, 0.003 mol) is added to a stirred solution of 8- cyclohexylmethoxy-4-(2-methoxy ethoxy)-2-methyl quinoline (0.7 g, 0.002 mol) in 1,4-dioxane (10 mL) at room temperature and then heated at 70°C for 30 minutes. Reaction mixture is cooled to room temperature, filtered through celite bed and washed with 1,4-dioxane (3x30 mL). Combined filtrate is concentrated under reduced pressure to get crude solid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 30:70) to furnish 8-cyclohexylmethoxy-4-(2- methoxy ethoxy)quinoline -2-carbaldehyde.
Step IV: Preparation of (R)-3-{[8-cyclohexyImethoxy-4-(2-methoxy ethoxy) quinoIin-2-ylmethyI]amino}piperidine-l-carboxylic acid tert-butyl ester.
Glacial acetic acid (0.04 mL, 0.0006 mol) followed by (R)-3-amino piperidine-1- carboxylic acid tert-butyl ester (0.3 g, 0.002 mol) is added to a stirred solution of 8- cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carbaldehyde (0.52 g, 0.002 mol) in dichloromethane (20 mL) at room temperature and stirred for 1 hr. Sodium cyanoborohydride (0.19 g, 0.003 mol) is added to the reaction mixture at room temperature and then stirred for 2 hrs. Reaction mixture is quenched with D. M. water (20 mL), organic layer is separated and aqueous layer is extracted with dichloromethane (2x30 mL). Combined organic layer is washed with brine solution (1x10 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:methanol, 90: 10) to get (R)-3- {[8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinolin-2-ylmethyl]amino}piperidine- 1-carboxylic acid tert-butyl ester. Step V: Preparation of (R)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinolin-2-yl methyl] isopropylamino} piperidine-l-carboxylic acid tert-butyl ester.
Glacial acetic acid (0.04 mL, 0.0006 mol) followed by acetone (0.52 mL) is added to a stirred solution of (R)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinolin-2- ylmethyl]amino}piperidine-l-carboxylic acid tert-butyl ester (0.26 g, 0.0005 mol) in dichloromethane (10 mL) at room temperature and stirred for 1 hr. Sodium cyanoborohydride (0.06 g, 0.001 mol) is added to the reaction mixture at room temperature and then stirred for 2 hrs. Reaction mixture is concentrated under reduced pressure at 45°C, D. M. water (15 mL) is added to the residue and this aqueous layer is extracted with dichloromethane (2x30 mL). Combined organic layer is washed with brine solution (1x10 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:methanol, 96:4) to get (R)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinolin-2-yl methyl] isopropyl amino} piperidine-l-carboxylic acid tert-butyl ester.
Step VI: Preparation of [8-cyclohexylmethoxy-4-(2-methoxyethoxy)quinolin-2-yl methyl]isopropyl-(R)-piperidin-3-yl amine trihydrochloride.
A solution of 4M hydrochloric acid in 1,4-dioxane (1 mL) is added to (R)-3-{[8-cyclo hexylmethoxy-4-(2-methoxyethoxy)quinolin-2-yl methyl]isopropylamino}piperidine- 1-carboxylic acid tert-butyl ester (0.18 g, 0.0003 mol) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane (2 mL) and again concentrated under reduced pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish [8-cyclohexylmethoxy-4-(2- methoxy ethoxy) quinolin-2-ylmethyl] isopropyl-(R)-piperidin-3-yl amine trihydrochloride.
Examples 123 and 124 are prepared according to the similar procedure as described in Example 122, using appropriate starting material and reagents.
Table 2:
Figure imgf000066_0001
formula (lb)
Figure imgf000066_0002
Example 125
4-(2-Acetylamino ethylsulfanvD-8-cvclopentylmethoxy quinoline-2-carboxyIic acid isopropyl-(R)-piperidin-3-yl amide dihydrochloride
Figure imgf000067_0001
Step I: Preparation of 4-chloro-8-cyclopentylmethoxy-2-methyl quinoline.
N,N-Di-isopropylethylamine (1.8 mL, 0.01 1 mol) is added to a stirred solution of cyclopentylmethanol (0.7 g, 0.007 mol) in dichloromethane (10 mL) at room temperature and stirred for 5 minutes. Reaction mixture is cooled to 0-5°C, methanesulphonylchloride (0.65 mL, 0.008 mol) is added dropwise to the reaction mixture and stirred for 30 minutes. D. M. water (10 mL) is added to the reaction mixture, organic layer is separated and aqueous layer is extracted with dichloromethane (2x20 mL). Combined organic layer is washed with D. M. water (1x10 mL) followed by brine solution (1x10 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure gives methanesulfonic acid cyclopentylmethyl ester, which is used directly for the next step.
Potassium carbonate (1.5 g, 0.011 mol) is added to a stirred solution of 4-chloro-2- methyl quinolin-8-ol (1.05 g, 0.005 mol) in N,N-dimethylformamide (8 mL) at room temperature and stirred for 15' minutes. A solution of methanesulfonic acid cyclopentylmethyl ester (1.25 g, 0.007 mol) in Ν,Ν-dimethyl formamide (7 mL) is added to the reaction mixture and then heated at 90°C for 5 hrs. Reaction mixture is cooled to 10-15°C, D. M. water (25 mL) is added and extracted with ethyl acetate (3x30 mL). Combined organic layer is washed with brine solution (2x30 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 10:90) to get 4-chloro-8-cyclopentylmethoxy- 2 -methyl quinoline.
Step II: Preparation of 4-chloro-8-cyclopentylmethoxy quinoline-2- carbaldehyde. Selenium dioxide (0.5 g, 0.004 mol) is added to a stirred solution of 4-chloro-8- cyclopentylmethoxy-2-methyl quinoline (1.05 g, 0.004 mol) in 1 ,4-dioxane (15 mL) at room temperature and then heated at 80°C for 15 minutes. Reaction mixture is cooled to room temperature, filtered through celite bed and washed with 1 ,4-dioxane (3x20 mL). Combined filtrate is concentrated under reduced pressure to get crude solid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 6:94) to furnish 4-chloro-8-cyclopentylmethoxy quinoline-2- carbaldehyde. ,<
Step III: Preparation of 4-chIoro-8-cyclopentylmethoxy quinoline-2-carboxylic acid. An aqueous solution (8 mL) containing sodium chlorite (0.67 g, 0.006 mol, 80%) and sodium dihydrogen orthophosphate dihydrate (1.87 g, 0.012 mol) is added to a heterogeneous solution of 4-chloro-8-cyclopentylmethoxy quinoline-2-carbaldehyde (0.58 g, 0.002 mol) in tert-butanol (15 mL) at room temperature and stirred for 2 hrs. Dichloromethane (25 mL) followed by D.M. water (20 mL) is added to the reaction mixture and stirred for 5 minutes. Organic layer is separated and aqueous layer is extracted with dichloromethane (2x25 mL). Combined organic layer is washed with brine solution (1x25 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure furnishes 4-chloro-8-cyclopentylmethoxy quinoline-2-carboxylic acid, which is directly used for the next step without purification. Step IV: Preparation of (R)-3-[(4-chloro-8-cyclopentylmethoxy quinoline-2- carbonyI)isopropylamino]piperidine-l-carboxylic acid ter/-butyl ester.
Oxalyl chloride (0.32 mL, 0.004 mol) is added dropwise to a stirred solution of 4- chloro-8-cyclopentylmethoxy quinoline-2-carboxylic acid (0.54 g, 0.002 mol) in dichloro methane (20 mL) at room temperature. N,N-Dimethylformamide (0.02 mL, 0.0003 mol) is added to the reaction mixture and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 40°C to get acid chloride derivative, which is directly used for the next step.
A solution of (R)-3-isopropylamino piperidine-l-carboxylic acid tert-butyl ester (0.5 g, 0.002 mol) and triethylamine (0.79 mL, 0.006 mol) in tetrahydrofuran (10 mL) is added to a stirred solution of 4-chloro-8-cyclopentylmethoxy quinoline-2-carbonyl chloride in tetrahydrofuran (5 mL) at room temperature and stirred for 2 hrs. Reaction mixture is quenched with D. M. water (5 mL) and concentrated under reduced pressure. Again, D. M. water (15 mL) is added to the residue and extracted with ethyl acetate (3x25 mL). Combined organic layer is washed with saturated sodium bicarbonate solution (1x20 mL) followed by D. M. water (1x20 mL) and brine solution (1x20 mL). Finally, it is dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 25:75) to furnish (R)-3-[(4-chloro-8-cyclopentylmethoxy quinoline-2-carbonyl) isopropylamino]- piperidine-l-carboxylic acid tert-butyl ester.
Step V: Preparation of (R)-3-{[4-(2-acetyIamino ethylsulfanyl)-8-cyclopentyl methoxy quinoline-2-carbonyl]isopropylamino}piperidine-l-carboxyIic acid tert- butyl ester. Potassium tert-butoxide (0.09 g, 0.0008 mol) is added to a stirred solution of N-(2- mercaptoethyl) acetamide (0.09 g, 0.0008 mol) in dimethylsulfoxide (3 mL) at room temperature and stirred for 10 minutes. A solution of (R)-3-[(4-chloro-8-cyclopentyl methoxy quinoline-2-carbonyl)isopropylamino]piperidine-l-carboxylic acid te -butyl ester (0.2 g, 0.0004 mol) in dimethylsulfoxide (3 mL) is added to the reaction mixture at room temperature and then heated at 60°C for 30 minutes. Reaction mixture is cooled to 10-15°C, ethyl acetate (15 mL) followed by D. M. water (15 mL) is added and stirred for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (3x25 mL). Combined organic layer is washed with D. M. water (1x20 mL) followed by brine solution (1x20 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure at 50°C gives crude solid, which is purified by column chromatography (silica gel 230-400 mesh, dichloromethane:methanol, 96:4) to get (R)-3-{[4-(2-acetylamino ethylsulfanyl)-8- cyclopentyl methoxy quinoline-2-carbonyl]isopropyl amino}piperidine-l-carboxylic acid tert-butyl ester.
Step VI: Preparation of 4-(2-acetylaminoethylsulfanyl)-8-cyclopentylmethoxy quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide dihydrochloride.
A solution of 4M hydrochloric acid in 1,4-dioxane (1.8 mL) is added to (R)-3-{[4-(2- acetylaminoethylsulfanyl)-8-cyclopentylmethoxy quinoline-2-carbonyl] isopropyl- amino}piperidine-l-carboxylic acid rt-butyl ester (0.18 g, 0.0003 mol) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane:methnol mixture (50:50, 2 mL) and again concentrated under reduced pressure at 58°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane:methnol mixture (50:50, 2 mL), concentrated and dried under reduced pressure to furnish 4-(2-acetylamino ethylsulfanyl)-8-cyclopentylmethoxy quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide dihydrochloride. Examples 126-129 are prepared according to the similar procedure as described in Example 125, using appropriate starting material and reagents.
Table 3:
Figure imgf000071_0001
formula Ic
Figure imgf000071_0003
Example 130
6-(2-Methoxy etho y)-2-methv. furo[3,2-h1quinoline-8-carboxylic acid isopropyl- (R)-piperidin-3-ylamide dihydrochloride
Figure imgf000071_0002
Step I: Preparation of l-nitro-2-prop-2-ynyloxy benzene.
Potassium carbonate (19.8 g, 0.144 mol) is added to a stirred solution of 2-nitro phenol (10.0 g, 0.071 mol) in N,N-dimethylformamide (100 mL) at room temperature and stirred for 15 minutes. Propargyl bromide (10.4 mL, 0.093 mol) is added to the reaction mixture and then heated at 65°C for 30 minutes. Reaction mixture is cooled to room temperature, filtered to remove potassium carbonate and then washed with ethyl acetate (2x50 mL). D. M. water (100 mL) is added to the combined filtrate, organic layer is separated and aqueous layer is extracted with ethyl acetate (2x100 mL). Combined organic layer is washed with D. M. water (1x50 mL) followed by brine solution (1x80 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure at 50°C to get l-nitro-2-prop-2-ynyloxy benzene, which is used for the next step without purification. Step II: Preparation of 2-methyl-7-nitro benzofuran.
A stirred solution of l-nitro-2-prop-2-ynyloxy benzene (15.6 g, 0.088 mol) in polyethylene glycol-200 (39 mL) is heated at 220°C for 1 hr and 30 minutes under nitrogen atmosphere. Reaction mixture is cooled to room temperature, poured into ice-water mixture (-100 mL) and then aqueous layer is extracted with diethyl ether (3x200 mL). Combined organic layer is dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain crude solid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 8:92) to get 2-methyl-7-nitro benzofuran.
Step III: Preparation of 2-methyl benzofuran-7-ylamine.
Stannous chloride (13.2 g, 0.07 mol) is added to a stirred solution of 2-methyl-7-nitro benzofuran (4.1 g, 0.023 mol) in methanol (41 mL) at room temperature. Concentrated hydrochloric acid (20.6 mL) is added to the reaction mixture and then heated at 75°C for 30 minutes. Methanol is removed under reduced pressure, D. M. water (30 mL) is added to the residue and reaction mixture is basified (pH~9) using aqueous sodium hydroxide solution (25%, 75 mL) at 0-5°C. It is then extracted with ethyl acetate (3x100 mL). Combined organic layer is washed with brine solution (1x50 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :toluene, 2:98) to get 2-methyl benzofuran-7- ylamine. Step IV: Preparation of 6-h droxy-2-methyl furo[3,2-h]quinoline-8-carboxylic acid methyl ester.
Dimethyl acetylenedicarboxylate (2.33 mL, 0.019 mol) is added to a solution of 2- methyl benzofuran-7-ylamine (2.8 g, 0.019 mol) in methanol (42 mL) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 50°C, the resulting liquid is added dropwise to a pre-heated solution of diphenyl ether (23 mL) at 250°C and then heating is continued for 15 minutes. Reaction mixture is cooled to room temperature, petroleum ether (40 mL) is added to it and stirred for 10 minutes. Petroleum ether layer is decanted and the crude material is purified by column chromatography (silica gel 230-400 mesh, dichloromethane:methanol, 98:2) to get 6-hydroxy-2 -methyl furo[3,2-h]quinoline-8- carboxylic acid methyl ester.
Step V: Preparation of 6-chloro-2-methy! furo[3,2-h]quinoline-8-carboxylic acid methyl ester.
Thionyl chloride (1.0 mL, 0.014 mol) is added dropwise to a solution of 6-hydroxy-2- methyl furo[3,2-h]quinoline-8-carboxylic acid methyl ester (2.2 g, 0.008 mol) in dichloromethane (22 mL) at room temperature. N,N-Dimethylformamide (0.97 mL, 0.013 mol) is added to the reaction mixture and then heated at 55°C for 1 hr and 30 minutes. Reaction mixture is cooled to room temperature and slowly added to saturated sodium bicarbonate solution (30 mL) at 0-5°C. Organic layer is separated and aqueous layer is extracted with dichloromethane (2x50 mL). Combined organic layer is washed with brine solution (1x50 mL) and dried over anhydrous sodium sulphate. Removal of dichloromethane under reduced pressure gives crude solid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 50:50) to get 6-chloro-2-methyl furo[3,2-h]quinoline-8-carboxylic acid methyl ester. Step VI: Preparation of 6-chloro-2-methyl furo[3,2-h]quinoline-8-carboxylic acid.
An aqueous solution (22.4 mL) of lithium hydroxide monohydrate (0.54 g, 0.013 mol) is added to a stirred solution of 6-chloro-2-methyl furo[3,2-h]quinoline-8- carboxylic acid methyl ester (1.45 g, 0.005 mol) in methanol (33.7 mL) at room temperature and then heated at 60°C for 1 hr. Methanol is removed under reduced pressure, D. M. water (12 mL) is added to the residue and aqueous layer is acidified (pH~6) using IN hydrochloric acid solution at 0-5°C. Solid precipitate thus obtained is filtered, washed with acetone (1x10 mL) and dried under reduced pressure to get 6- chloro-2-methyl furo[3,2-h]quinoline-8-carboxylic acid, which is used directly for the next step.
Step VII: Preparation of (R)-3-[(6-chloro-2-methyl furo[3,2-h]quinoline-8- carbonyl)isopropylamino]piperidine-l-carboxylic acid ter/-butyl ester.
Oxalyl chloride (0.3 mL, 0.003 mol) is added dropwise to a stirred solution of 6- chloro-2-methyl furo[3,2-h]quinoline-8-carboxylic acid (0.45 g, 0.002 mol) in dichloromethane (10 mL) at room temperature. N,N-Dimethylformamide (0.02 mL, 0.0003 mol) is added to the reaction mixture and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure at 40°C to get acid chloride derivative, which is directly used for the next step.
A solution of (R)-3-isopropylamino piperidine-1 -carboxylic acid tert-butyl ester (0.4 g, 0.002 mol) and triethylamine (0.7 mL, 0.005 mol) in tetrahydrofuran (5 mL) is added to a stirred solution of 6-chloro-2-methyl furo[3,2-h]quinoline-8-carbonyl chloride in tetrahydrofuran (5 mL) at room temperature and stirred for 2 hrs. Reaction mixture is quenched with D. M. water (5 mL) and concentrated under reduced pressure. Again, D. M. water (15 mL) is added to the residue and aqueous layer is extracted with ethyl acetate (3x40 mL). Combined organic layer is washed with saturated sodium bicarbonate solution (1x20 mL) followed by D. M. water (1x20 mL) and brine solution (1x20 mL). Removal of ethyl acetate layer under reduced pressure after drying over anhydrous sodium sulphate gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 30:70) to furnish (R)-3-[(6-chloro-2 -methyl furo[3,2-h]quinoline-8-carbonyl)isopropylamino]- piperidine-l-carboxylic acid tert-butyl ester.
Step VIII: Preparation of (R)-3-{isopropyI-[6-(2-methoxy ethoxy)-2-methyl furo
[3,2-h]quinoIine-8-carbonyl]amino}piperidine-l-carboxylic acid butyl ester.
Potassium tert-butoxide (0.08 g, 0.0007 mol) is added to a stirred solution of 2- methoxy ethanol (0.05 mL, 0.0007 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 5 minutes. A solution of (R)-3-[(6-chloro-2-methyl furo[3,2-h]quinoline-8-carbonyl)isopropylamino]piperidine-l-carboxylic acid tert- butyl ester (0.25 g, 0.0005 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr. Reaction mixture is cooled to 10- 15°C, ethyl acetate (25 mL) followed by D. M. water (12 mL) is added to the reaction mixture and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x25 mL). Combined organic layer is washed with D. M. water (1x20 mL) followed by brine solution (1x20 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure at 50°C gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 65:35) to get (R)-3-{isopropyl-[6-(2-methoxy ethoxy)- 2-methyl furo[3,2-h]quinoline-8-carbonyl]amino}piperidine-l-carboxylic acid tert- butyl ester.
Step IX: Preparation of 6-(2-methoxy ethoxy)-2-methyl furo[3,2-h]quinoline-8- carboxylic acid isopropyI-(R)-piperidin -3-yl amide dihydrochloride. A solution of 4M hydrochloric acid in 1,4-dioxane (0.9 mL) is added to (R)-3- {isopropyl-[6-(2-methoxy ethoxy)-2-methyl furo[3,2-h]quinoline-8-carbonyl]amino} piperidine-l-carboxylic acid teri-butyl ester (0.16 g, 0.0003 mol) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane:methanol mixture(50:50, 2 mL) and again concentrated under reduced pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane:methanol mixture(50:50, 2 mL), concentrated and dried under reduced pressure to furnish 6-(2-methoxy ethoxy)-2-methyl furo[3,2-h] quinoline-8-carboxylic acid isopropyl-(R)-piperidin -3-yl amide dihydrochloride. Examples 131-133 are prepared according to the similar procedure as described in Example 130, using appropriate starting material and reagent.
Table 4:
Figure imgf000076_0001
formula (Id)
Figure imgf000077_0001
Example 134
8-Cvclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide dihydrochloride
Figure imgf000077_0002
Step I: Preparation of (S)-3-[(4-chIoro-8-cycIohexylmethoxyquinoline-2- carbonyl)-isopropylamino]pyrrolidine-l-carboxylic acid tert-butyl ester.
Thionyl chloride (0.18 mL, 0.003 mol) is added dropwise to a stirred solution of 4- chloro-8-cyclohexylmethoxy quinoline-2-carboxylic acid (0.4 g, 0.001 mol) in dichloromethane (8 mL) at room temperature. N,N-Dimethylformamide (0.05 mL, 0.0006 mol) is added to the reaction mixture and heated at 50°C for 1 hr. Reaction mixture is concentrated under reduced pressure at 40°C to get acid chloride derivative, which is directly used for the next step.
A solution of (S)-3-isopropylamino pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.29 g, 0.001 mol) and triethylamine (0.52 mL, 0.004 mol) in tetrahydrofuran (5 mL) is added to a stirred solution of 4-chloro-8-cyclohexylmethoxy quinoline-2-carbonyl chloride in tetrahydrofuran (5 mL) at room temperature and stirred for 2 hrs. Reaction mixture is quenched with D. M. water (5 mL) and concentrated under reduced pressure. Again, D. M. water (10 mL) is added to the residue and extracted with ethyl acetate (3x25 mL). Combined organic layer is washed with saturated sodium bicarbonate solution (1x20 mL) followed by D. M. water (1x20 mL) and brine solution (1 x20 mL). Finally, it is dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 20:80) to furnish (S)-3-[(4-chloro-8-cyclohexylmethoxy quinoline-2-carbonyl) isopropylamino]- pyrrolidine- 1-carboxylic acid tert-butyl ester.
Step II: Preparation of (S)-3-{[8-cycIohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isopropylamino}pyrrolidine-l-carboxylic acid tert-butyl ester.
r
Potassium tert-butoxide (0.1 1 g, 0.001 mol) is added to a stirred solution of 2- methoxy ethanol (0.07 mL, 0.0009 mol) in dimethyl sulfoxide (3 mL) at room temperature and stirred for 10 minutes. A solution of (S)-3-[(4-chloro-8- cyclohexylmethoxy quinoline-2-carbonyl)isopropylamino]pyrrolidine-l -carboxylic acid tert-butyl ester (0.39 g, 0.0007 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr. Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted With ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 60:40) to get (S)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carbonyl]isopropylamino}pyrrolidine-l -carboxylic acid tert-butyl ester.
Step III: Preparation of 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2- ; carboxylic acid isopropyI-(S)-pyrrolidin-3-yl amide dihydrochloride.
A solution of 4M hydrochloric acid in 1 ,4-dioxane (1.3 mL) is added to (S)-3-{[8- cyclohexy lmethoxy-4-(2-methoxy ethoxy)quinol ine-2-carbonyl] isopropylamino } - pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.26 g, 0.0005 mol) at room temperature and stirred for 30 minutes. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane (2 mL) and again concentrated under reduced pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide dihydrochloride.
Examples 135-145 are prepared according to the similar procedure as described in Example 134, using appropriate starting material and reagent.
Table 5:
Figure imgf000080_0001
formula (Ie)
Figure imgf000080_0003
Example 146
8-Cvclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isobutyl- (R)-piperidin-3-yl amide dihydrochloride
Figure imgf000080_0002
Step I: Preparation of (R)-3-[(4-chloro-8-cycIohexylmethoxy quinoIine-2- carbonyl) isobutylamino] piperidine-l-carboxylic acid tert-butyl ester. Thionyl chloride (0.2 mL, 0.003 mol) is added dropwise to a stirred solution of 4- chloro-8-cyclohexylmethoxy quinoline-2-carboxylic acid (0.3 g, 0.0009 mol) in dichloromethane (10 mL) at room temperature. N,N-Dimethylformamide (0.01 mL, 0.0002 mol) is added to the reaction mixture and heated at 60°C for 1 hr. Reaction mixture is concentrated under reduced pressure at 40°C to get the acid chloride derivative, which is directly used for the next step.
A solution of (R)-3-isobutylamino piperidine-l-carboxylic acid teri-butyl ester (0.24 g, 0.0009 mol) and triethylamine (0.4 mL, 0.003 mol) in tetrahydrofuran (6 mL) is added to a stirred solution of 4-chloro-8-cyclohexylmethoxy quinoline-2-carbonyl chloride in tetrahydrofuran (6 mL) at room temperature and stirred for 2 hrs. Reaction mixture is quenched with D. M. water (10 mL) and concentrated under reduced pressure. Again, D. M. water (50 mL) is added to the residue and extracted with ethyl acetate (3x75 mL). Combined organic layer is washed with saturated sodium bicarbonate solution (1x50 mL) followed by D. M. water (1x50 mL) and brine solution (1x50 mL). Finally, it is dried over anhydrous sodium sulphate and concentrated under reduced pressure to get crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane, 20:80) to furnish (R)-3-[(4-chloro-8-cyelohexylmethoxy quinoline-2-carbonyl) isobutylamino] piperidine-l-carboxylic acid tert-butyl ester. Step II: Preparation of (R)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isobutylamino}piperidine-l-carboxylic acid tert-buty\ ester.
Potassium tert-butoxide (0.08 g, 0.0007 mol) is added to a stirred solution of 2- methoxy ethanol (0.06 mL, 0.0008 mol) in dimethyl sulfoxide (4 mL) at room temperature and stirred for 10 minutes. A solution of (R)-3-[(4-chloro-8- cyclohexylmethoxy quinoline-2-carbonyl)isobutylamino]piperidine- 1 -carboxylic acid tert-butyl ester (0.32 g, 0.0006 mol) in dimethyl sulfoxide (4 mL) is added to the reaction mixture at room temperature and stirred for 1 hr. Reaction mixture is cooled to 10-15°C, ethyl acetate (20 mL) followed by D. M. water (15 mL) is added and stirred vigorously for 5 minutes. Organic layer is separated and aqueous layer is extracted with ethyl acetate (2x20 mL). Combined organic layer is washed with D. M. water (1x15 mL) followed by brine solution (1x15 mL) and dried over anhydrous sodium sulphate. Removal of ethyl acetate under reduced pressure gives crude liquid, which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate :n-hexane, 50:50) to get (R)-3-{[8-cyclohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl]isobutylamino}piperidine-l-carboxylic acid tert-butyl ester.
Step III: Preparation of 8-cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isobutyl-(R)-piperidin-3-yl amide dihydrochloride.
A solution of 4M hydrochloric acid in 1 ,4-dioxane (1.3 mL) is added to (R)-3-{[8- cyclohexylmethoxy-4-(2-methoxy ethoxy) quinoline-2-carbonyl] isobutylamino} piperidine-l-carboxylic acid tert-butyl ester (0.26 g, 0.0004 mol) and stirred for 30 minutes at room temperature. Reaction mixture is concentrated under reduced pressure, residue is dissolved in dichloromethane (2 mL) and again concentrated under reduced pressure at 55°C. Diethyl ether is added to the residue, content is titurated with spatula and then diethyl ether layer is decant-off. Residue is redissolved in dichloromethane, concentrated and dried under reduced pressure to furnish 8- cyclohexylmethoxy-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isobutyl-(R)- piperidin-3-yl amide dihydrochloride.
Examples 147-149 are prepared according to the similar procedure as described in Example 146, using appropriate starting material and reagents. Table 6:
Figure imgf000083_0001
formula (If)
Figure imgf000083_0002
Measurement of human renin inhibition ;
The inhibitory effect of the NCEs on Human Renin was evaluated using the SensoLyte®520 Renin Assay Kit (Catalog No.- 72040) from Anaspec. Test compound/vehicle was preincubated with recombinant human renin for 30 minutes at 37°C in a 96-well plate. Renin Substrate was added and incubated for another 15 minutes, after which the fluorescence intensity was measured on Multimode Reader at 490nm as Excitation/Emission = 490nm/520nm. All the reagents were prepared and used according to the kit literature. The results of some representative compounds of the present invention measured according to the above-mentioned method are shown in Table 7. Table 7: Human renin inhibitory activity
Figure imgf000083_0003
17 86.39 a
29 97 97 a
75 84.41 8
80 98.46 a
124 56.64 b
125 93.21 a
131 58.67 b
133 49.90 b
134 45.23 b
147 81.05 b
149 71.1 1 b
% inhibition at 10 nM; b % inhibition at / 100 nM
All publications and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.

Claims

We claim:
1. A compound of formula (I),
Figure imgf000085_0001
formula (I)
or pharmaceutically acceptable salt thereof,
wherein;
X is selected from O or S;
Y is bond or a group selected from O or NH, with the proviso that Y is NH when X is s;
Z is a group selected from -CO, -CH2 ;
R is selected from the group consisting of substituted or unsubstituted -Ci.s-linear or branched alkyl, -C3.8-cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci_3 -linear or branched alkyl group;
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3.i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO- C3-i2-cycloalkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COCi.8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC,-8-alkyl, -COOC3.i2- cycloalkyl, -S02C1.8-alkyl, -S02-aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical, and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, and 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6
R2 is selected from the group consisting of substituted or unsubstituted -Ci-i2-linear or branched alkyl - -(CH2)q-C3.]2-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3.,2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C,.8-alkyl, -(CH2)qCO-C3.12-cycloalkyl, - (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COC,.8-alkyl, -COC3-]2-cycloalkyl, -CO- aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6, with proviso that R2 is -C7-i2-linear or branched alkyl when Z is -CO,; R is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted -Ci-8-alkyl, -C3_i2-cycloalkyl;
or OR2 and R3 together with the carbon atom to which they are attached form a 3 to 6-
membered cyclic ring system, ring V of the formula
Figure imgf000086_0001
(R ) , with optional one or more double bond, R" is a substitutent selected from -Ci.g-alkyl or -C3.i2- cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
'n' is an integer selected from 0, 1 and 2;
'mi ', 'm2' and 'm3' are integers independently selected from 0, 1, 2, 3 and 4;
( * ) at the ring carbon, indicate (R) or (5) configuration or a racemate (RS).
2. A compound of formula (la),
Figure imgf000086_0002
formula (la) or pharmaceutically acceptable salt thereof,
wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -C].8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- Ci-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COCi-8-alkyl, -COC3-i2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-12-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7-i2-linear or branched alkyl, -(CH2)q-C3-,2-cycioalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, - (CH2)qCO-heteroaryl, -COCi-8-alkyl, -COC3-12-cycloalkyl, -CO- aryl, -COOC(-8-alkyl, -COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS). 3. A compound of formula (lb),
Figure imgf000087_0001
formula (lb)
or pharmaceutically acceptable salt thereof,
wherein;
Y is bond or oxygen (O);
1 is selected from the group consisting of substituted or unsubstituted -Ci.8-linear or branched alkyl, -C3-]2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- Ci.g-alkyl, -(CH2)qCO-C3.i2-cycloalkyl, -(CH2)qCO-aryl, -COC1 -8-alkyl, -COC3-12- cycloalkyl, -CO-aryl, -COOCi.g-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -(CH2)q-C3-12-cycloalkyl, -(CH2)qO-Ci.8-alkyl, -(CH2)qO-C3.i2- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-Ci-8-alkyl, -(CH2)qCO-C3-12-cycloalkyl, - (CH2)qCO-aryl, -COQ.g-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOCi-8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2,
3, 4, 5 or 6; 'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS).
4. A compound of formula (Ic),
Figure imgf000088_0001
formula (Ic)
or pharmaceutically acceptable salt thereof, r
wherein;
R1 is selected from the group consisting of substituted o unsubstituted -Ci-8-linear or branched alkyl, -C3.i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- Ci.g-alkyl, -(CH2)qCO-C3.) 2-cycloalkyl, -(CH2)qCO-aryl, -COC]-8-alkyl, -COC3-!2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-r2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -Ci.8-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl, -(CH2)qO-C]-8-alkyl, -(CH2)qO-C3-12- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C,-8-alkyl, -(CH2)qCO-C3-12-cycloalkyl, - (CH2)qCO-aryl, -COQ.s-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC,.8-alkyl, - COOC3.i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS).
5. A compound of formula (Id),
Figure imgf000089_0001
formula (Id)
or pharmaceutically acceptable salt thereof,
wherein;
Y is bond or oxygen (O);
R1 is selected from the group consisting of substituted or unsubstituted -Ci-s-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- C.8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, -(CH2)qCO-aryl, -COC,.8-alkyl, -COC3- I2- cycloalkyl, -CO-aryl, -COOQ.g-alkyl, -COOC3.i2-cycloalkyl, -S02C,-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
ring 'c' of the formula
Figure imgf000089_0002
, contains optionally one or more double bond;
R" is a substitutent selected from -Ci-8-alkyl or -C3-]2-cycloalkyl and 'p' is an integer selected from 0, 1 or 2;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS).
6. A compound of formula (Ie),
Figure imgf000089_0003
formula (Ie)
or pharmaceutically acceptable salt thereof,
wherein;
Y is bond or oxygen (O);
X is selected from O or S;
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci.8-alkyl, -(CH2)qCO- Cs-alkyl, -(CH2)qCO-C3-12-cycloalkyl, -(CH2)qCO-aryl, -COC1-8-alkyl, -COC3-i2- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7.]2-linear or branched alkyl, -(CH2)q-C3-12-cycloalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qO-C3-12- cycloalkyl, -(CH2)qO-aralkyl, -(CH2)qCO-C1-8-alkyl, -(CH2)qCO-C3-i2-cycloalkyl, - (CH2)qCO-aryl, -COC,.8-alkyl, -COC3.i2-cycloalkyl, -CO-aryl, -COOCi-8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1, 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
'mi ', 'm2' and 'm3' are integers independently selected from 0, 1 , 2, 3 and 4;
( * ) at the ring carbon indicate (i?) or (S) configuration or racemate (RS).
7. A compound of formula (If),
Figure imgf000090_0001
formula (If) or pharmaceutically acceptable salt thereof,
wherein;
v.
Y is bond or oxygen (O);
R is selected from the group consisting of substituted or unsubstituted -Ci-5-linear or branched alkyl, -C3.8-cycloalkyl and cycloalkylalkyl; wherein cycloalkyl group may be optionally substituted with Ci-3-linear or branched alkyl group.
R1 is selected from the group consisting of substituted or unsubstituted -Ci-8-linear or branched alkyl, -C3-i2-cycloalkyl, cycloalkylalkyl, -(CH2)qO-Ci-8-alkyl, -(CH2)qCO- Ci-8-alkyl, -(CH2)qCO-C3.12-cycloalkyl, -(CH2)qCO-aryl, -COd.g-alkyl, -COC3- 12- cycloalkyl, -CO-aryl, -COOCi-8-alkyl, -COOC3-i2-cycloalkyl, -S02Ci-8-alkyl, -S02- aryl, aryl, aralkyl, heteroaryl, and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
R2 is selected from the group consisting of substituted or unsubstituted -C7-i2-linear or branched alkyl, -(CH2)q-C3-i2-cycloalkyl -, -(CH2)qO-C[-8-alkyl, -(CH2)qO-C3-i2- cycloalkyl, -(C¾)qO-aralkyl, -(CH2)qCO-Ci-8-alkyl, -(CH2)qCO-C3.,2-cycloalkyl, - (CH2)qCO-aryl, -COCi.8-alkyl, -COC3-i2-cycloalkyl, -CO-aryl, -COOC1 -8-alkyl, - COOC3-i2-cycloalkyl, aralkyl aryl, heteroaryl and a heterocyclic radical and may contain one or more heteroatom selected from O, S and N in the cycloalkyl or heterocyclic ring system, 'q' is an integer selected from 0, 1 , 2, 3, 4, 5 or 6;
'n' is an integer selected from 0, 1 and 2;
( * ) at the piperidin-3-yl carbon, indicate (R) or (S) configuration or racemate (RS).
8. A compound according to any one of the preceeding claims, selected from the group consisting of:
8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
4-(2-Methoxyethoxy)-8-[(R)-(tetrahydrofuran-3-yl)oxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 8-Benzyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(tetrahydrofuran-2-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-(4-Fluorobenzyloxy)-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-[(S)- 1 -(tetrahydrofuran-2-yl)methoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(tetrahydropyran-4-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(3-Cyclopentylpropoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 4-(2-Methoxyethoxy)-8-phenethyloxyquinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• 8-(4-Isopropyl cyclohexylmethoxy)-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-[4-(4-Chlorophenyl)cyclohexylmethoxy]-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(2-propylpentyloxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide; • 8-(Indan-2-yloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-3-yl amide;
• 8-(2-Cyclohexylethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-(4-Isobutylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(4-Isopropylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(4-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(4-Cyclohexylbenzyloxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Heptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)- piperidin-3-yl amide; · 8-[2-(4-Fluorophenyl)ethoxy]-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(5-oxohexyloxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclooctyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-(pyridin-2-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 4-(2-Methoxyethoxy)-8-(pyridin-3-ylmethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxyethoxy)-8-[2-(2-oxo pyrrolidin- 1 -yl)ethoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-(2,2-Dimethoxyethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclohexylmethoxy-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-(3-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-(4-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(3-Chlorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl -(R)-piperidin-3-yl amide;
• 4-(3-Methoxypropoxy)-8-(3-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Fluorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 8-Benzyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• 4-(3-Methoxypropoxy)-8-(tetrahydrofuran-2-ylmethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 4-(3-Methoxypropoxy)-8-[(R)-(tetrahydrofuran-3-yl)oxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2,3-Dichlorobenzyloxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(3-Methoxypropoxy)-8-[(S)-l-(tetrahydrofuran-2-yl)methoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclooctyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-Heptyloxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide; · 8-Cyclohexylmethoxy-4-(3-methoxy propoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(3-ethoxypropoxy)quinoline-2 -carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• Carbonic acid-2-[8-cycloheptyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester methyl ester;
• Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinol in -4-yloxy] ethyl ester methyl ester; • Carbonic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl- carbamoyl) quinolin-4-yloxy]ethyl ester methyl ester;
• Carbonic acid-2-[8-isobutoxy-2-((R)-isopropylpiperidin-3-yl- carbamoyl)quinolin-4-yloxy]ethyl ester methyl ester; · Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester ethyl ester;
• Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]ethyl ester pentyl ester;
• Carbonic acid-2-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy] ethyl ester isobutyl ester;
• Carbonic acid-3-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl- carbamoyl) quinolin-4-yloxy]propyl ester methyl ester;
• Carbonic acid-3-[8-cyclopentyloxy-2-((R)-isopropylpiperidin-3-yl-carbamoyl) quinolin-4-yloxy]propyl ester methyl ester; · 8-Cycloheptyloxy-4-(2-isobutoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(2-propoxyethoxy)quinoline-2-carboxylic acid isopropyl- (R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(2-cyclopropylmethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Cyclohexyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 4-(2-Methoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 4-(2-Methoxyethoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Adamantan- 1 -yl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Cyclopropyl-2-oxoethoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-[2-(4-Chlorophenyl)-2-oxoethoxy]-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-[2-Cyclopropyl-l-(2-fluoro phenyl)-2-oxo ethoxy]-4-(2-methoxy
ethoxy)quinoline -2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-[2-(3-Chloro phenyl)-2-oxo ethoxy]-4-(2-methoxy ethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Furan-2-yl-2-oxo ethoxy)-4-(2-methoxy ethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Methoxy ethoxy)-8-(2-oxo-2-thiophen-2-yl ethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; 4-(2-Ethoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-ethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(3 ,3 -Dimethyl-2-oxobutoxy)-4-(2-ethoxyethoxy)quinol ine-2-carboxyl ic acid isopropyl-(R)-piperidin-3-yl amide;
4-(2-Ethoxyethoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl -(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclohexyl-2-oxoethoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(3-Methoxypropoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8-(2-Cyclopentyl-2-oxoethoxy)-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
4-(3-Methoxypropoxy)-8-(3-methyl-2-oxobutoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
8 -Cyclohexy lmethoxy-4-(2-methoxymethoxyethoxy)quino 1 ine-2-carboxy 1 ic acid isopropyl-(R)-piperidin-3-yl amide;
8-Isobutoxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 8-Cycloheptyloxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclopentyloxy-4-(2-methoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-Cyclopentyloxy-4-(2-ethoxymethoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclohexylmethoxy-4-(3-methoxymethoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cycloheptyloxy-4-(3-methoxymethoxypropoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxymethoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-(2-Cyclopentyl-2-oxoethoxy)-4-(2-methoxymethoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 4-(2-Methoxymethoxyethoxy)-8-(4-methyl-2-oxopentyloxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-[(R)-2-(2,2-Dimethylpropionylamino)butoxy]-4-(2- methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; · 8-[(S)-2-(2,2-Dimethylpropionylamino)butoxy]-4-(2- methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 8-((R)-2-Methanesulfonylaminobutoxy)-4-(2-methoxyethoxy)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• Carbonic acid isobutyl ester-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester; · 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (S)-piperidin-3-yl amide;
• 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-piperidin-3-yl amide;
• Isobutyric acid-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy) quinolin-8-yl ester;
• 2,2-Dimethyl propionic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
• Pentanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy) quinolin-8-yl ester; · Hexanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy) quinolin-8-yl ester;
• Heptanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy) quinolin-8-yl ester;
• Octanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy) quinolin-8-yl ester;
• Cyclopropanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester; • Cyclopentanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
• Cyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester; · 1- Methylcyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl- carbamoyl)-4-(2-methoxy ethoxy)quinolin-8-yl ester;
• Adamantane-l-carboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4- (2-methoxy ethoxy)quinolin-8-yl ester;
• 3-Cyclopentylpropionic acid-2-((R)-isopropyl-piperidin-3-yl-carbamoyl)-4-(2- methoxyethoxy)quinolinT8-yl ester;
• 4-Fluorobenzoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(2- methoxy ethoxy)quinolin-8-yl ester;
• Pentanoic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxyprdpoxy) quinolin-8-yl ester; · Cyclopropanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxy propoxy)quinolin-8-yl ester;
• Cyclopentanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxy propoxy)quinolin-8-yl ester;
• Cyclohexanecarboxylic acid-2-((R)-isopropylpiperidin-3-yl-carbamoyl)-4-(3- methoxy propoxy)quinolin-8-yl ester;
• Hexanoic acid-2-((R)-isopropyl piperidin-3-yl-carbamoyl)-4-(3- methoxypropoxy) quinolin-8-yl ester; • 4-(2-Methoxyethoxy)-8-methoxymethoxy quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Benzyloxymethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide; · 4-(2-Benzyloxyethoxy)-8-cyclohexylmethoxy quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl-amide;
• 8-Cyclohexylmethoxy-4-[2-(3,3-dimethyl-2-oxobutoxy)ethoxy]quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• Acetic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropylpiperidin-3-yl- carbamoyl) quinolin-4-yloxy]ethyl ester;
• Isobutyric acid-2-[8-cyclohexylmethoxy-2-((R)-isopropyl piperidin-3-yl- carbamoyl) quinolin-4-yloxy]ethyl ester;
• 2,2-Dimethyl propionic acid-2-[8-cyclohexylmethoxy-2-((R)-isopropyl piperidin-3-yl carbamoyl)quinolin-4-yloxy]ethyl ester; · 8-Cyclopentyloxy-4-(2-methoxybenzyloxy)quinoline-2-carboxylic acid
isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclopentyloxy-4-(2,3-dichloro benzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 8-Cyclopentyloxy-4-(2-trifluoromethylbenzyloxy)quinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• [8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl- (R)-piperidin-3-yl amine; • [8-Cyclopentyloxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl-(R)- piperidin -3-yl amine;
• [8-Cycloheptyloxy-4-(2-methoxyethoxy)quinolin-2-ylmethyl]isopropyl-(R)- piperidin -3-yl amine; · 4-(2-Acetylaminoethylsulfanyl)-8-cyclopentylmethoxyquinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Acetylaminoethylsulfanyl)-8-cyclopentyloxyquinoline-2-carboxylic acid i sopropy l-(R)-p iper idin-3 -y 1 am ide ;
• 8-Cyclopentyloxy-4-(2-methanesulfonylaminoethylsulfanyl)quinoline-2- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Acetylaminoethylsulfanyl)-8-benzyloxyquinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 4-(2-Benzoylaminoethylsulfanyl)-8-cyclopentyloxyquinoline-2-carboxylic acid isopropyl-(R)-piperidin-3-yl-amide; · 6-(2-Methoxyethoxy)-2-methyl-furo[3,2-h]quinoline-8-carboxylic acid
isopropyl-(R)-piperidin-3-yl-amide;
• 6-(3-Methoxypropoxy)-2-methyl-furo[3,2-h]quinoline-8-carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 6-(2-Methoxyethoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8- carboxylic acid isopropyl-(R)-piperidin-3-yl amide;
• 6-(3-Methoxypropoxy)-2,2-dimethyl-2,3-dihydrofuro[3,2-h]quinoline-8- carboxylic acid isopropyl-(R)-piperidin-3-yl amide; • 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide;
• 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (S)-pyrrolidin-3-yl amide; · 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(S)-pyrrolidin-3-yl amide;
• 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl- (S)-l-pyrrolidin-2-ylmethyl amide; f
• 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(S)-l-pyrrolidin-2-ylmethyl amide;
• 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl piperidin-2-ylmethyl amide;
• 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl piperidin-2-ylmethyl amide; · 8-Cycloheptyloxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid azetidin- 3-yl isopropyl amide;
• 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl-(R)- 1 -piperidin-3-ylmethyl amide;
• 8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isopropyl-(R)-l-piperidin-3-ylmethyl amide;
• 8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid
isopropyl piperidin-4-yl amide; 8-Cyclohexylmethoxy-4-(3-methoxypropoxy)quinoline-2-carboxylic acid isopropyl piperidin-4-yl amide;
8-CycIohexyImethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isobutyl-(R)-piperidin-3-yl amide;
8-Cyclohexylmethoxy-4-(2-methoxyethoxy)quinoline-2-carboxylic acid cyclopentyl-(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid isobutyl-(R)-piperidin-3-yl amide;
8-(3,3-Dimethyl-2-oxobutoxy)-4-(2-methoxyethoxy)quinoline-2-carboxylic acid cyclopentyl-(R)-piperidin-3-yl amide
PCT/IN2012/000726 2011-11-11 2012-11-06 Quinoline derivatives as renin inhibitors WO2013088452A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3177MU2011 2011-11-11
IN3177/MUM/2011 2011-11-11

Publications (2)

Publication Number Publication Date
WO2013088452A2 true WO2013088452A2 (en) 2013-06-20
WO2013088452A3 WO2013088452A3 (en) 2013-10-03

Family

ID=48048100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000726 WO2013088452A2 (en) 2011-11-11 2012-11-06 Quinoline derivatives as renin inhibitors

Country Status (1)

Country Link
WO (1) WO2013088452A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009311A1 (en) 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
WO2007099509A2 (en) 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
WO2008136457A1 (en) 2007-04-27 2008-11-13 Dainippon Sumitomo Pharma Co., Ltd. Nitrogen-containing aromatic derivative
JP2010208947A (en) 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd Quinolone derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009311A1 (en) 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
WO2007099509A2 (en) 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
WO2008136457A1 (en) 2007-04-27 2008-11-13 Dainippon Sumitomo Pharma Co., Ltd. Nitrogen-containing aromatic derivative
JP2010163361A (en) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd Quinoline derivative
JP2010208947A (en) 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd Quinolone derivative

Also Published As

Publication number Publication date
WO2013088452A3 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
CN106659914B (en) Inhibitors of lysine-specific demethylase-1
JP6273621B2 (en) Histone demethylase inhibitor
EP2496559A1 (en) Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
CA2608072A1 (en) Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2007058305A1 (en) Process for production of cinnamamide derivative
JP2017537947A (en) Heterocyclic compounds as antibiotic potentiators
RU2591190C2 (en) Novel 4-amino-n-hydroxybenzamides as hdac inhibitors for treating cancer
EA027533B1 (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CA2611711A1 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
EP1888569A1 (en) Substituted piperidines as renin inhibitors
CA2816136A1 (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors
KR101651722B1 (en) Nitrogen-containng saturated heterocyclic compound
US8138352B2 (en) Method for producing asymmetric tetrasubstituted carbon atom-containing compound
JP7288161B2 (en) Novel dihydroquinazolinone compound or pharmacologically acceptable salt thereof, and cell growth inhibitor
WO2013088452A2 (en) Quinoline derivatives as renin inhibitors
Hong et al. A novel approach to Finafloxacin hydrochloride (BAY35-3377)
HU194879B (en) Process for producing 1,6-naphtiridine derivatives and pharmaceutical compositions containing them
SK172799A3 (en) 3-benzylpiperidine derivative, process for its preparation and pharmaceutical composition containing the same
WO2005108400A1 (en) Pyridoquinazoline derivatives having heterobicyclic substituents
JPH05345777A (en) 7-@(3754/24)4,4-dialkyl-3-amino-substituted pyrrolidinyl)-quinolone-3-carboxylic acid derivative
US5668131A (en) Substituted aminoalkylaminopyridines
RU2527459C1 (en) Novel heteroarene anthracenedione-based g-quadruplex ligands inhibiting tumour cell growth
JP4011819B2 (en) Process for producing indole derivatives and intermediates thereof
KR100888468B1 (en) 1&#39;-Alkylpiperidine-4&#39;-spiro-2-6-amido-2H-benzopyran derivatives having anticancer activity
KR101116754B1 (en) 6-Amino-N-hydroxyhexanamide compounds having inhibitory activity against histone deacetylase, and method for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12839180

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12839180

Country of ref document: EP

Kind code of ref document: A2